WO1995030642A1 - Combinatorial dihydrobenzopyran library - Google Patents

Combinatorial dihydrobenzopyran library Download PDF

Info

Publication number
WO1995030642A1
WO1995030642A1 PCT/US1995/005940 US9505940W WO9530642A1 WO 1995030642 A1 WO1995030642 A1 WO 1995030642A1 US 9505940 W US9505940 W US 9505940W WO 9530642 A1 WO9530642 A1 WO 9530642A1
Authority
WO
WIPO (PCT)
Prior art keywords
lower alkyl
aryl
resin
substituted
compound
Prior art date
Application number
PCT/US1995/005940
Other languages
French (fr)
Inventor
John J. Baldwin
John C. Reader
Lawrence W. Dillard
Jonathan J. Burbaum
Wenguang Zeng
Ge Li
Original Assignee
Pharmacopeia, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacopeia, Inc. filed Critical Pharmacopeia, Inc.
Priority to AU25869/95A priority Critical patent/AU691296B2/en
Priority to EP95920411A priority patent/EP0758313A4/en
Priority to JP7529207A priority patent/JPH10500112A/en
Publication of WO1995030642A1 publication Critical patent/WO1995030642A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/59—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures

Definitions

  • 93/20242 describe a synthesis wherein oligonucleotides are produced in parallel with and are chemically linked as genetic tags to oligopeptides as the compounds of interest.
  • WO 93/06121 teaches methods for particle-based synthesis of random oligomers wherein identification tags on the particles are used to facilitate identification of the oligomer sequence synthesized.
  • a detachable tagging system is described in Ohlmeyer et al., Proc. Natl. Acad. Sci. USA, 90, 10922- 10926, Dec. 1993.
  • the present invention relates to combinatorial chemical libraries of compounds encoded with tags and to the use of these libraries in assays to discover biologically active compounds.
  • the present invention also relates to libraries containing
  • the present invention also relates to members of the library which interact (i.e., as agonists or antagonists) with ⁇ adrenergic receptors, dopamine receptors, ⁇ -opiate receptors, and K + channels.
  • the present invention also relates to members of the library which are inhibitors of carbonic anhydrase.
  • the invention also relates to methods for their preparation, intermediates, and to methods and pharmaceutical formulations for using these dihydrobenzopyrans in the treatment of mammals, especially humans. Because of their activity as inhibitors of carbonic anhydrase isozymes, compounds of the present invention are useful in the treatment of such diseases as glaucoma.
  • s is a solid support
  • T'-L- is an identifier residue
  • -L'-II' is a ligand/linker residue
  • Preferred compounds of Formula I are those wherein:
  • T'-L- is of the Formula:
  • n 3-12 when Ar is pentachlorophenyl
  • n 3-6 when Ar is 2,4,6-trichlorophenyl
  • the ligands of Formula II may be detached by photolytic, oxidative, or other cleavage techniques.
  • -L'- is (b) and B is O (or
  • photolytic detachment may be represented by:
  • R 1 is OH, O(CH 2 ) 1-2 OH, OCH 2 CO 2 H, CO 2 H,
  • R 2 is H or lower alkyl
  • R 3 is H, alkyl, aryl, or arylalkyl
  • R 4 and R 5 is each independently H, lower alkyl, or substituted lower alkyl where the substituents are 1-3 alkoxy, aryl, substituted aryl, carboalkoxy, carboxamido, or diloweralkylamido; or R 4 and R 5 taken together are
  • R 6 and R 7 is H and the other is H, OH, or N(CH 2 ) 1-6 R 14 R 15 ; or R 6 and R 7 taken together are , , , or ;
  • R 8 is H, COOR 9 , CONHR 10 , CSNHR 11 , COR 12 , SO 2 R 13, lower alkyl, aryl lower alkyl, heteroaryl, or heteroaryl lower alkyl, wherein aryl is optionally substituted with 1-3 substituents selected from lower alkyl, lower alkoxy, halo, CN, NH 2 , COOH, CONH 2 , carboalkoxy, and mono- or di- lower alkylamino and wherein heteroaryl is a mono- or bicyclic heteroaromatic ring system of 5 to 10 members including 1 to 3 heteroatoms selected from O, N, and S and 0-3 substituents selected from halo, amino, cyano, lower alkyl, carboalkoxy, CONH 2 , and S-lower alkyl;
  • R 9 is lower alkyl, aryl, aryl lower alkyl, heteroaryl, aryl
  • heteroaryl is a heteroaromatic ring of 5 to 6 members including 1 to 2 heteroatoms selected from O, N, and S and 0-2 substituents selected from lower alkyl, dialkylamino, lower alkoxy, and halo;
  • R 10 and R 11 is each independently lower alkyl, aryl, aryl lower alkyl, or aryl substituted by 1-3 substituents selected from lower alkyl, halo, alkoxy, and haloalkyl;
  • R 12 is lower alkyl, aryl, heteroaryl, aryl lower alkyl,
  • heteroaryl lower alkyl a 5- or 6-membered heterocyclic ring containing 1-2 heteroatoms selected from O, S, and N, a 5- or 6-membered heterocyclic ring containing 1-2 heteroatoms selected from O, S, and N lower alkyl, or aryl substituted with 1-3 substituents selected from lower alkyl, alkoxy, halo, sulfamoyl, lower alkyl sulfamoyl, cyano, and phenyl;
  • R 13 is lower alkyl, aryl, or aryl substituted with 1-3 substituents selected from lower alkyl, alkoxy, halo, CN, and haloalkyl;
  • R 14 is H; alkyl substituted by 1-3 alkoxy, S-loweralkyl,
  • sulfamoyl halo, alkylsulphonamido, or arylsulphonamido; alkenyl; alkynyl; aryl; substituted aryl; heteroaryl;
  • R 15 is H, alkyl, -C(O)X, -C(S)X, or -C(NCN)NR 3 R 3 ;
  • R 16 is lower alkyl, substituted lower alkyl, aryl, or substituted aryl;
  • R 17 is H; alkyl substituted by 1-3 alkoxy, S-loweralkyl,
  • sulfamoyl halo, alkylsulphonamido, or arylsulphonamido; alkenyl; alkynyl; aryl; substituted aryl; heteroaryl;
  • X is alkyl, aryl, arylalkyl, O-loweralkyl, or NR 3 R 3
  • Z is -(CH 2 ) 1-6 -, optionally substituted with 1-3 lower alkyl;
  • n 2 or 3;
  • n 4-9;
  • Preferred compounds of Formula II are those wherein R 12 is sulfamoylphenyl, most preferably p-sulfamoylphenyl.
  • a preferred embodiment of the invention is a compound of
  • R 1 is OH, OCH 2 C(O)NH(CH 2 ) 1-6 R 14 , or OCH 2 -4-Phe- C(O)NH(CH 2 ) 1-6 R 14 ;
  • R 2 is H or lower alkyl; R 4 and R 5 is each lower alkyl; or R 4 and R 5 taken together are
  • R 8 is H, COOR 9 , CONHR 10 , CSNHR 11 , COR 12 , SO 2 R 13 , .
  • R 9 is lower alkyl, aryl lower alkyl, aryl, tetrahydrofuranyl, tetrahydropyranyl, or aryl substituted by 1 to 2 substituents selected from lower alkyl, alkenyl, alkoxy, methylene dioxy, and halo;
  • R 10 and R 11 is each independently aryl, aryl lower alkyl, or aryl
  • R 12 is lower alkyl, aryl, aryl lower alkyl, heteroaryl lower alkyl wherein the heteroatoms are N, a 5- or 6-membered heterocyclic ring containing 1-2 heteroatoms selected from S and N lower alkyl, or aryl substituted with 1 substituent selected from lower alkyl, alkoxy, halo, sulfamoyl, cyano, or phenyl;
  • R 13 is lower alkyl, aryl, or aryl substituted with 1 substituent selected from lower alkyl, alkoxy, and halo; or a pharmaceutically acceptable salt thereof.
  • Most preferred compounds of the invention are represented by the formula:
  • R 1 is 6- or 7-OH
  • R 2 is H or lower alkyl
  • R 4 and R 5 is each methyl; or R 4 and R 5 taken together are -(CH 2 ) 5 -,
  • R 8 i is H, COOR 9 , CONHR 10 , CSNHR 1 1 , COR 12 , SO 2 R 13 , benzyl, -CH 2 -Ph-4-F, -CH 2 -Ph-4-OCH 3 , -CH 2 -4-Py, n-butyl, -CH 2 -c-propyl, , or
  • R 9 is i-propyl, phenyl, phenethyl, t-butyl,
  • R 10 is phenyl, p-chlorophenyl, or p-trifluoromethylphenyl
  • R 11 is phenyl, benzyl, or 1-naphthyl
  • R 12 is , , , , , , ,
  • R 13 is 1- or 2-naphthyl, phenyl, 4-chlorophenyl, 4- methylphenyl, 4-t-butylphenyl, n-butyl, or i-propyl;
  • R 1 is 6- or 7-OH when R 2 is H;
  • R 1 is 7-OH when R 2 is CH 3 ;
  • R 4 and R 5 is each methyl; or R 4 and R 5 taken together are -(CH 2 ) 5 -,
  • R 1 is 6- or 7-OCH 2 C(O)NH(CH 2 ) 1-6 R 17 , or 6- or 7-OCH 2 -4- Phe-C(O)NH(CH 2 ) 1-6 R 17 when R 2 is H;
  • R 1 is 7-OCH 2 C(O)NH(CH 2 ) 1-6 R 17 , or 7-OCH 2 -4-Phe- C(O)NH(CH 2 ) 1-6 R 17 when R 2 is CH 3 ;
  • R 4 and R 5 is each methyl; or R 4 and R 5 taken together are -(CH 2 ) 5 -,
  • R 8 is H, CONHCH 3 , SO 2 Ph, (CH 2 ) 3 CH 3 , CO(CH 2 ) 2 CH 3 , benzyl, -C(O)-(4-Phe)-SO 2 NH 2 , or ;
  • R 13 is
  • R 14 is methyl, n-butyl, 3-methoxy-n-propyl, CH 2 -c-propyl, or
  • R 17 is methyl, 2-methoxyethyl, 2-phenylethyl,
  • inhibitors of carbonic anhydrase are compounds of formulae IIb, IIc, and IId:
  • R 1 is 6- or 7-OH, 6- or 7-OCH 2 C(O)NH(CH 2 ) 1-6 R 17 , or
  • R 2 is H or CH 3 ;
  • R 8 is -CO-Ph-p-SO 2 NH 2 ;
  • R 14 and R 17 may each be any pharmacologically relevent orgaic radical, such as those derived by removal of H 2 NCH 2 - from the following compounds:
  • an aspect of the invention is a method of identifying a compound having a desired characteristic which comprises synthesizing a combinatorial library of Formula I and testing the compounds of Formula I and the ligands of Formula II, either attached to the solid support or detached therefrom, in an assay which identifies compounds having the desired
  • a further embodiment of the invention is determining the structure of any compound so identified.
  • R 2 is H or lower alkyl
  • R is allyl or methyl and b) when R is allyl reacting said compound with methylene chloride, tetrakistriphenylphosphine palladium(0), and pyrrol idine and stirring the mixture at 0°C, or when R is methyl reacting said compound with dilute NaOH and THF and stirring the mixture at 0°C.
  • R allyl is preferable to the t-butyl or methyl esters since the milder conditions would not induce aldol type condensation of the acetophenone portion of the molecule.
  • Another embodiment of the invention is a method for identifying compounds that are inhibitors of carbonic anhydrase which comprises preparing a mixture of 20-300 pmol test compound and aqueous solutions (total volume: 25-100, preferably about 50, ⁇ L) of 0.03-0.12, preferably about 0.06, ⁇ M carbonic anhydrase and 0.04- 0.16, preferably about 0.08, ⁇ M dansylamide, exposing said mixture to U.V. (preferably 274 nm) light, and determining the amount of emitted U.V. (preferably 454 nm) light.
  • U.V. preferably 274 nm
  • U.V. preferably 454 nm
  • Another embodiment of the invention is a method for identifying compounds that are enzyme inhibitors which is a lawn assay which comprises contacting a colloidal matrix containing enzyme, which matrix has embedded therein a mono-layer of solid supports with attached ligands, with a layer of fluorogenic substrate-containing material, eluting said ligands by exposure to U.V. light, and detecting zones of inhibition in the colloidal matrix produced thereby.
  • a preferred such lawn assay comprises contacting an agarose matrix containing bovine carbonic anhydrase with a fluorescein diacetate-containing layer of agarose.
  • s is a solid support
  • R is H or alkyl
  • R 16 is lower alkyl, substituted lower alkyl, aryl, or substituted aryl;
  • R 17 is H; alkyl substituted by 1-3 alkoxy, S-loweralkyl,
  • sulfamoyl halo, alkylsulphonamido, or arylsulphonamido; alkenyl; alkynyl; aryl; substituted aryl; heteroaryl;
  • Y is aryl or heteroaryl.
  • Compounds of formula 14 are useful as intermediates in the construction of combinatorial libraries and are especially useful in automated or batch mode syntheses thereof.
  • Boc t-butyloxycarbonyl
  • DBU 1,8-diazabicyclo[5,4,0]undec-7-ene
  • FACS fluorescence activated cell sorting
  • HOBt N-hydroxybenzotriazole
  • PEG polyethylene glycol
  • Ph phenyl
  • Alkyl is intended to include linear, branched, or cyclic structures and combinations thereof of from 1 to 20 carbon atoms.
  • “Lower alkyl” includes alkyl groups of from 1 to 8 carbon atoms.
  • lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s- and t-butyl, pentyl, hexyl, octyl, c-propyl, c-butyl and the like.
  • Lower cycloalkyl includes cycloalkyl groups of from 3 to 8 carbon atoms. Examples of lower cycloalkyl groups include c-propyl, c-butyl, c-pentyl, 2-methylcyclopropyl, cyclopropylmethyl, and the like.
  • Alkenyl is C 2 -C 6 alkenyl of a linear, branched, or cyclic
  • alkenyl groups include allyl, isopropenyl, pentenyl, hexenyl, c-hexenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, and the like.
  • Alkynyl is C 2 -C 6 alkynyl of a linear, branched, or cyclic (C 5 -C 6 ) configuration and combinations thereof.
  • alkynyl groups include ethynyl, propargyl, 3-methyl-1-pentynyl, 2-heptynyl isopropynyl, pentynyl, hexynyl, c-hexynyl, 1-propynyl, 2-butynyl, 2-methyl-2-butynyl, and the like.
  • Alkoxy means alkoxy groups of from 1 to 6 carbon atoms of a straight, branched, or cyclic configuration. Examples of alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy, and the like.
  • Substituted loweralkyl means lower alkyl substituted with 1-3 alkoxy, carboalkoxy, carboxamido, di-loweralkylamino, aryl, substituted aryl, or heteroaryl.
  • Aryl means phenyl or naphthyl.
  • Substituted aryl means aryl substituted with 1-3 halo, loweralkyl, alkoxy, aryl, S-loweralkyl, alkylsulphonamido,
  • Heteroaryl means a 5 or 6 membered aromatic ring containing 1-3 hetero atoms selected from O, N, and S.
  • Substituted heteroaryl means heteroaryl substituted with 1-3 halo, loweralkyl, alkoxy, aryl, S-loweralkyl, alkylsulphonamido, arylsulphonamido, or sulfamoyl.
  • Heterocycloalky means lower cycloalkyl containing 1-3 hetero atoms selected from O, N, and S.
  • Halogen includes F, Cl, Br, and I.
  • L and L' are depicted in Table 1 , which also shows cleavage reagents.
  • the left-hand bond is the point of attachment to the solid support and the right-hand bond is the point of attachment to either T or II.
  • the tags of this invention, T are chemical entities which possess several properties: they must be detachable from the solid supports, preferably by photolysis or oxidation; they must be
  • the tags may be structurally related or unrelated, e.g., a homologous series, repetitive functional groups, related members of the Periodic Chart, different isotopes, combinations thereof, and the like. At the end of the combinatorial synthesis, to each solid support, there will usually be attached at least 0.01 femtomol, usually 0.001-50 pmol, of each tag.
  • the tags may be aliphatic, alicyclic, aromatic, heterocyclic, or combinations thereof.
  • Distinguishing features may be the number of repetitive units, such as methylene groups in an alkyl moiety; alkyleneoxy groups in a
  • polyalkyleneoxy moiety halo groups in a polyhalo compound; ⁇ -and/or ⁇ -substituted ethylene groups where the substituents may be alkyl groups, oxy, carboxy, amino, halo, or the like; isotopes; etc.
  • solid supports The materials upon which the combinatorial syntheses of the invention are performed are referred to as solid supports, beads, and resins. These terms are intended to include:
  • beads, pellets, disks, fibers, gels, or particles such as cellulose beads, controlled pore-glass beads, silica gels, polystyrene beads optionally cross-linked with divinylbenzene and optionally grafted with polyethylene glycol and optionally functionalized with amino, hydroxy, carboxy, or halo groups, grafted co-poly beads, polyacrylamide beads, latex beads, dimethylacrylamide beads optionally cross-linked with N,N'-bis-acryloyl ethylene diamine, glass particles coated with hydrophobic polymer, etc., i.e., material having a rigid or semi-rigid surface; and
  • soluble supports such as low molecular weight non-cross-linked polystyrene. It is intended that the definitions of any substituent or symbol (e.g., R 3 ) in a particular molecule be independent of its definitions elsewhere in the molecule. Thus, NR 3 R 3 represents NH 2 , NHCH 3 , N(CH 3 ) 2 , etc.
  • Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms which may be defined in terms of absolute stereochemistry as (R) or (S).
  • the present invention is meant to comprehend all such possible diastereomers as well as their racemic and optically pure forms and mixtures thereof.
  • Optically active (R) and (S) forms may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques.
  • the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended to include both E and Z geometric isomers. Likewise, all tautomeric forms are intended to be included.
  • compositions of the present invention comprise a compound of Formula II as an active ingredient or a pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier and, optionally, other therapeutic ingredients.
  • pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic acids or bases including organic and inorganic acids or bases.
  • salts may be prepared from pharmaceutically acceptable non-toxic bases. Salts derived from all stable forms of inorganic bases include
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion-exchange resins such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine,
  • ethylenediamine N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, isopropylamine, lysine, methylglucosamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, etc.
  • salts may be prepared from pharmaceutically acceptable non-toxic acids.
  • acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic, etc.
  • Particularly preferred are citric, hydrobromic, maleic, phosphoric, sulfuric, and tartaric acids.
  • the ability of the compounds of Formula II to interact with ⁇ adrenergic receptors indicates that the compounds are useful to treat, prevent, or ameliorate hypertension and benign prostate hypertrophy in mammals, especially in humans.
  • the ability of the compounds of Formula II to interact with dopamine receptors indicates that the compounds are useful to treat, prevent, or ameliorate Alzheimer's disease and depression in humans.
  • the ability of the compounds of Formula II to interact with ⁇ -opiate receptors indicates that the compounds are useful to treat, prevent, or ameliorate schizophrenia in mammals, especially in humans.
  • K + channels indicates that the compounds are useful to treat, prevent, or ameliorate hypertension, asthma, and pulmonary insufficiency in mammals, especially in humans.
  • the magnitude of the prophylactic or therapeutic dose of the compounds of Formula II will vary with the nature and severity of the condition to be treated and with the particular compound of
  • the daily dose range for anti-enzymic use lies in the range of 20 to 0.001 mg/kg body weight of a mammal, preferably 10 to 0.01 mg/kg, and most preferably 1.0 to 0.1 mg/kg, in single or divided doses. In some cases, it may be necessary to use doses outside these ranges.
  • a suitable daily dosage range is from about 10 to 0.0005 mg (preferably 5 to 0.01 mg) compound of Formula II per kg body weight.
  • a suitable daily dosage range is from about 20 to 0.001 mg (preferably 10 to 0.01 mg) compound of Formula II per kg body weight.
  • a suitable daily dosage range is from about 10-0.01 %
  • compound of Formula II typically prepared as a 2.0-0.1 % by weight solution or suspension of a compound of Formula II in an acceptable ophthalmic formulation.
  • the compounds of Formula II may also be used in combination with other pharmaceutically active ingredients.
  • a typical ocular formulation may comprise the compound alone or in combination with a ⁇ -adrenergic blocking agent such as timolol maleate or a parasympathomimetic agent such as pilocarpine.
  • a ⁇ -adrenergic blocking agent such as timolol maleate or a parasympathomimetic agent such as pilocarpine.
  • the two active ingredients are present in approximately equal parts.
  • Any suitable route of administration may be employed for providing a mammal, especially a human, with an effective dosage of a compound of Formula II.
  • a route of administration may be employed for providing a mammal, especially a human, with an effective dosage of a compound of Formula II.
  • oral, rectal, topical, parenteral, ocular, pulmonary, nasal, etc. routes may be employed.
  • Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like.
  • compositions of the present invention comprise a compound of Formula II, or a pharmaceutically acceptable salt thereof, as an active ingredient, and may also contain a
  • compositions include compositions suitable for oral, rectal, topical (including transdermal devices, aerosols, creams, ointments, lotions, and dusting powders), parenteral (including subcutaneous, intramuscular, and intravenous), ocular (ophthalmic), pulmonary (nasal or buccal inhalation), or nasal administration;
  • a compound of Formula II may be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending on the nature of the preparation desired for administration, i.e., oral, parenteral, etc.
  • any of the usual pharmaceutical media may be used, such as water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like in the case of oral liquid preparations (e.g., suspensions, elixirs, and solutions); or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, etc.
  • capsules in the case of oral solid preparations such as powders, capsules, and tablets. Solid oral preparations are preferred over liquid oral preparations. Because of their ease of administration, tablets and capsules are the preferred oral dosage unit form. If desired, capsules may be coated by standard aqueous or non-aqueous techniques.
  • the compounds of Formula II may be administered by controlled release means and devices such as those described in U.S.P. Nos. 3,536,809; 3,598,123; 3,630,200; 3,845,770; 3,916,899; and 4,008,719, which are incorporated herein by reference.
  • compositions of the present invention suitable for oral administration may be prepared as discrete units such as capsules, cachets, or tablets each containing a predetermined amount of the active ingredient in powder or granular form or as a solution or suspension in an aqueous or nonaqueous liquid or in an oil-in-water or water-in-oil emulsion.
  • Such compositions may be prepared by any of the methods known in the art of pharmacy. In general, the compositions are prepared by uniformly and intimately admixing the active
  • a tablet may be prepared by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as powder or granule optionally mixed with a binder, lubricant, inert diluent, or surface active or dispersing agent.
  • Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
  • Ophthalmic inserts are made from compression molded films which are prepared on a Carver Press by subjecting the powdered mixture of active ingredient and HPC to a compression force of 12,000 lb. (gauge) at 149°C for 1-4 min. The film is cooled under pressure by having cold water circulate in the platen. The inserts are then
  • each insert is placed in a vial, which is then placed in a humidity cabinet (88% relative humidity at 30°C) for 2-4 days. After removal from the cabinet, the vials are capped and then autoclaved at 121°C for 0.5 hr.
  • These compounds of Formulae I and II may also be used as libraries for discovering new lead structures by evaluation across an array of biological assays, including the discovery of selective inhibition patterns across isozymes. These libraries are thus tools for drug discovery; i.e., as a means to discover novel lead compounds by screening the libraries against a variety of biological targets and to develop structure-activity relationships in large families of related compounds.
  • the libraries may be tested with the ligands attached to the solid supports as depicted in Formula I or the individual compounds II may be detached prior to evaluation.
  • screening assays such as FACS sorting, bead lawn assays, and cell lawn assays may be used.
  • the compounds of the present invention may be tested by assays well known in the art for interaction with ⁇ adrenergic
  • carbonic anhydrase inhibition assays are: Carbonic Anhydrase Inhibition - Maren and Couto, "The
  • Carbonic Anhydrase Inhibition It has now been found that the use of very low initial concentrations (0.04-1.6, preferably about 0.6, ⁇ M) of dansylamide and (0.03-1.2, preferably about 0.3, ⁇ M) of carbonic anhydrase to assay test compounds for carbonic anhydrase inhibition not only allows the use of very small total volumes (approx. 25-100, preferably about, 50 ⁇ L) per assay but also allows one to distinguish high-affinity from low-affinity compounds without either re-elution or re-synthesis of the test compound.
  • Reactions are carried out in 50 ⁇ L total volume in 96-well plates, preferably, Dynatech MicroFluor plates, white with 'U' bottom, containing the test compounds.
  • the assay mix is prepared immediately before use, and 50 ⁇ L of the assay solution is pipetted into each well of plates in which the test compounds are previously dried. The plates are spun briefly in a tabletop centrifuge before reading fluorescence.
  • Fluorescence is read in a Perkin-Elmer LS 50B spectrofluorimeter fitted with a Well Plate Reader Accessory using an excitation
  • An enzyme of interest is incorporated into a gellable gum such as silica gel, agar, agarose, pectin, polyacrylamide, gelatin, starch, and gellan gum, preferably a low melting-temperature agarose gel (0.5-2.0%, wt./vol.), which is layered on top of a lawn, no greater than one bead in thickness, of solid supports with attached ligands.
  • a gellable gum such as silica gel, agar, agarose, pectin, polyacrylamide, gelatin, starch, and gellan gum, preferably a low melting-temperature agarose gel (0.5-2.0%, wt./vol.), which is layered on top of a lawn, no greater than one bead in thickness, of solid supports with attached ligands.
  • the detection of an active combinatorial library member is accomplished by photoeluting the ligands from the beads in situ by exposure to U.V. light. To minimize premature photoelution,
  • the beads are evaluated by placing a second layer, preferably low-melt agarose gel, containing a substrate on top of the one containing the enzyme and the photoreleased library members, and allowing enzymic conversion of substrate into product by diffusion of the substrate into the enzyme-containing gel.
  • the substrate is preferably one that produces a photometric change upon conversion into product; e.g., the generation of a colored product, a fluorescent product, or a chemiluminescent reaction (where one of the products is a photon).
  • the second layer may comprise a gellable gum such as silica gel, agar, agarose, pectin, polyacrylamide, gelatin, starch, and gellan gum, or a solid material such as a matrix containing an array of fluorogenic-pellets.
  • a gellable gum such as silica gel, agar, agarose, pectin, polyacrylamide, gelatin, starch, and gellan gum
  • a solid material such as a matrix containing an array of fluorogenic-pellets.
  • This technique may be used with a variety of enzymes, for example:
  • a bead lawn assay for testing carbonic anhydrase inhibition preferably comprises agarose for both layers, bovine carbonic anhydrase, and fluorescein diacetate.
  • Bead Lawn Assay (Carbonic Anhydrase). Beads to be tested are arrayed in a minimal amount of methanol in a 60 mm polystyrene tissue culture dish and then all the methanol allowed to evaporate. A 2.5% (wt./vol.) mixture of agarose (SeaPlaque, FMC BioProducts, Rockland, ME) in 20 mM sodium phosphate buffer (pH 7.4) is heated on a hot plate until the agarose dissolves and then is equilibrated to 37°C in a water bath. A separate stock of the same buffer is also equilibrated to 37°C.
  • the enzyme layer is prepared as follows: 100 ⁇ L of a bovine carbonic anhydrase stock (0.5 mg/mL or 53 ⁇ M based on absorbance at 280 nm, Sigma #C-3934) is added to 2.15 mL of buffer, and 1.25 mL agarose solution is added to the mixture. The agarose/enzyme solution is poured onto the dish containing the beads and the agarose is allowed to solidify at r.t. for 3-5 min. To identify zones of inhibition, the compounds, which are optionally photoeluted by exposure to 4.7-6 mW/cm 2 365 nm UV light for 5 sec.
  • FLDA fluorescein diacetate
  • the buffer used is 20 mM Tris, 1 mM EGTA, pH 7.8.
  • the enzyme layer contains 1 mg/mL recombinant human inositol monophosphatase (purified from E. col ⁇ ) and 10 mM MgCl 2 .
  • the preferred substrate is CSPD.
  • the compounds of the present invention can be prepared according to the following methods.
  • each solid support upon which a compound is being synthesized is uniquely tagged to define the particular chemical event(s) occurring during that step.
  • the tagging is accomplished using identifiers such as those of Formula IV, which record the sequential events to which the support is exposed during the synthesis, thus providing a reaction history for the compound produced on each support.
  • the identifiers are used in combination with one another to form a binary or higher order encoding scheme permitting a relatively small number of identifiers to encode a relatively large number of reaction products. For example, when used in a binary code, N identifiers can encode up to 2 N different compounds and/or conditions.
  • identifiers which uniquely define the chosen variables such as reactant, reagent, reaction conditions, or combinations of these, one can use the identifiers to define the reaction history of each solid support.
  • one begins with at least 10 3 , desirably at least 10 4 , and generally not exceeding 10 15 solid supports.
  • the supports accordingly into as many containers.
  • the appropriate reagents and reaction conditions are applied to each container and the combination of identifiers which encode for each R 1 /R 2 choice is added and attached.
  • the tagging may be done prior to, concomitantly with, or after the reactions which comprise each choice.
  • sample supports may be picked at any stage and a portion of their tags detached and decoded to verify that the correct tags are bound to the sample supports.
  • the supports are usually combined, mixed, and again divided, this time into as many containers as pre determined for the number of choices for the second step in the synthesis. This procedure of dividing, reacting, tagging, and remixing is repeated until the combinatorial synthesis is completed.
  • Functionalized supports such as amino-functionalized or hydroxy-terminating PEG grafted polystyrene beads are divided into a pre-determined number of reaction vessels and are reacted with a cleavable linker/ligand element 3, which has been pre-formed, to generate 4.
  • Unique tagging of the supports in each reaction vessel is achieved with combinations of identifiers encoded in a binary scheme, e.g., as depicted in Table 1-1 for three choices of R 1 and R 2 .
  • the identifiers are attached by adding a solution of the identifiers (in a 1.5% wt./wt. identifier:solid support ratio) to a batch of supports suspended in CH 2 Cl 2 and shaking the mixture for 30 min.
  • Unique tagging of the supports in each reaction vessel is achieved with combinations of additional identifiers encoded in a binary scheme, e.g., as depicted in Table 1-2 for seven choices of R 4 R 5 .
  • the compounds 5c where R 4 /R 5 /X represents the residue of piperidine, pyrrolidine, or aminocyclohexane, are pooled, mixed, and then divided into a pre-determined number of reaction vessels.
  • the supports in each reaction vessel are uniquely tagged with combinations of additional identifiers encoded in a binary scheme, e.g., as depicted in Table 1-3 for 30 choices of R 8 and in Table 1-5 for six choices of R 14 and four choices of heteroaryl groups.
  • each reaction vessel is treated with one reagent corresponding to ligand element R 8 in the presence of solvents such as CH 2 Cl 2 , DMF, or EtOH and, when required, bases such as triethylamine or 2,6-lutidine to produce 6 having an R 8 substituent at C-2 and a ketone at C-4, i.e., when R 6 R 7 together are O.
  • R 14 is benzyl, -CH 2 -Ph-4-F, -CH 2 -Ph-4-OCH 3 , -CH 2 -4-Py, n-pentyl, or-CH 2 -c-propyl; and heteroaryl is , or
  • a portion of the compounds 5a, 5b, 5c, and 6 may be pooled, mixed, and then divided into a pre-determined number of reaction vessels where they may be uniquely tagged with combinations of additional identifiers encoded in a binary scheme, e.g., as in Table 1-4 for three choices of R 6 /R 7 .
  • Each vessel is treated with sodium borohydride to yield 7 as an alcohol at C-4 or is treated with 1,2-dithioethane and a Lewis acid such as BF 3 •Et 2 O to yield 8 as a dithiolane at C-4, or is treated with an appropriate non-beta branched primary amine in the presence of NaCNBH 3 in MeOH, optionally with acetic acid, to yield secondary amine 9, or is left untreated.
  • a Lewis acid such as BF 3 •Et 2 O
  • Compounds 5a, 5b, 5c, 5d, 6, 7, 8 , and 9 are then exposed to UV light (-360 nm) in polar solvents such as DMSO, H 2 O, or a lower alkanol such as MeOH to cleave the compounds of Formula II from the support/linker complex.
  • polar solvents such as DMSO, H 2 O, or a lower alkanol such as MeOH to cleave the compounds of Formula II from the support/linker complex.
  • TentaGel resin may be modified with bis-Boc Lysine to increase the available reaction sites for ligand attachment Bis-Boc-lysine in DMF, HOBt, and DIC are shaken at r.t. and then dry TentaGel resin is added. The mixture is shaken at r.t. for 17 hr and then washed alternately with methanol and DCM and then with THF and dried under vacuum. To deprotect the resin, DCM is added, followed by a 30 % TFA solution in DCM (100 mL). The vessel is shaken at room temperature for 15 min. before adding neat TFA.. The vessel is shaken at room temperature for 2.5 hr at which time the resin is washed with DCM, then treated with a solution of 10% triethylamine in DCM, then washed with DCM and DMF.
  • Functionalized supports such as amino-functionalized or hydroxy-terminating PEG grafted polystyrene beads are divided into a pre-determined number of reaction vessels and are reacted with a cleavable linker/ligand element 10, which has been pre-formed, to generate 1 1.
  • Unique tagging of the supports in each reaction vessel is achieved with combinations of identifiers encoded in a binary scheme, e.g., as depicted in Table 2-1 for seven choices of -(CH 2 ) 1-6 R 17 .
  • the identifiers are attached by adding a solution of the identifiers (in a 7% wt./wt. identifie ⁇ solid support ratio) to each batch of supports suspended in EtOAc and shaking the mixture for 1 hr.
  • a dilute solution of rhodium trifluoroacetate dimer in DCM is added and the mixture is shaken 15 hr and washed with DCM (4X) and EtOAc (2X). The procedure is repeated for each identifier.
  • the compounds 12 are pooled, mixed, and divided into a pre-determined number of reaction vessels, each of which is treated with one acetophenone reagent corresponding to ligand element R 2 , in the presence of DIC, HOBt, and DMF to produce 4'.
  • Unique tagging of the supports in each reaction vessel is achieved with combinations of additional identifiers encoded in a binary scheme analogous to that in
  • the compounds 4' are mixed, pooled, and divided into a predetermined number of reaction vessels, each of which is treated with and aldehyde or ketone element corresponding to R 4 /R 5 in the presence of pyrrolidine in methanol at 75°C to produce the compounds 5a', 5b', and 5c'.
  • Unique tagging of the supports in each reaction vessel is achieved with combinations of additional identifiers encoded in a binary scheme analogous to that in Table 2-1.
  • R 4 /R 5 /X represents the residue of t-Boc protected piperidine, t-Boc protected aminocyclohexane, or other amine functionalized molecules are mixed, pooled, and divided into a predetermined number of reaction vessels.
  • the supports in each reaction vessel are uniquely tagged with combinations of additional identifiers encoded in a binary scheme analogous to that in Table 2-1.
  • each vessel is treated with one reagent such as a chloroformate, isocyanate,
  • thioisocyanate carboxylic acid, alkyl or aryl sulfonyl halide, aldehyde, or a haloheteroaromatic compound corresponding to ligand element R 8 in the presence of solvents such as CH 2 Cl 2 , DMF, EtOH, or methanol.
  • solvents such as CH 2 Cl 2 , DMF, EtOH, or methanol.
  • bases such as triethylamine, DBU, or 2,6-lutidine and/or other reagents or combinations of reagents such as DIC,
  • NaCNBH 3 , HOBt, and acetic acid are added to produce 6 ', having an R 8 substituent at C-2 and a ketone at C-4, i.e. when R 6 R 7 together are O.
  • a portion of compounds 5a', 5b', 5c', and &. may be pooled, mixed, and then divided into a pre-determined number of reaction vessels where they may be uniquely tagged with combinations of additional identifiers encoded in a binary scheme analogous to that in Table 2-1.
  • Each vessel is treated with 1) sodium borohydride in methanol to yield 7' as an alcohol at C-4; 2) 1 ,2-dithioethane and a Lewis acid such as boron trifluoride etherate to yield 81 as the dithiolane at C-4; 3) an unhindered primary amine along with
  • the compounds 9 or 9 ' are divided into a predetermined number of reaction vessels.
  • Each vessel is treated with one reagent such as a chloroformate, isocyanate, thioisocyanate, carboxylic acid, alkyl or aryl sulfonyl halide, aldehyde, or a haloheteroaromatic compound corresponding to ligand element R 15 in the presence of solvents such as CH 2 Cl 2 , DMF, EtOH, or methanol.
  • bases such as triethylamine, DBU, or 2,6-lutidine and/or other reagents or
  • Functionalized supports such as amino-functionalized or hydroxy-terminating PEG grafted polystyrene beads are placed into a reaction vessel and are reacted with a cleavable linker/ligand element 10, which has been pre-formed, to generate 1 1'.
  • a cleavable linker/ligand element 10 which has been pre-formed, to generate 1 1'.
  • To deprotect the resin it is suspended in DCM and ther agitated with a TFA solution in DCM. The resin is then washed with DCM followed by treatment with triethylamine in DCM and then washed with DCM to yield 12'.
  • the amino resin 12' (1 equiv. of amino sites).
  • a solvent such as DCM is added, followed by an organic base such as triethylamine, pyridine, Hiinig's base (di-isopropylethylamine), or 2,6-lutidine (10 equiv.).
  • the resin is agitated for 4 hrs. and then washed with DCM and MeOH (5X each) to yield 14.
  • n 3-12 and Ar is pentachlorophenyl or
  • n 5-6 and Ar is 2,4,6-trichlorophenyl
  • the crude material was dissolved in 100 mL toluene, 10 mL (1.63 g, 14 mmol ) thionyl chloride was added, and the mixture was refluxed for 90 min. The volume of the solution was reduced to approx. 30 mL by distillation, then the remaining toluene was removed by evaporation.
  • Step (c) there is a change to the final diazomethylation step, whereby the ao.d chloride is reacted with (trimethylsilyl)diazomethane and triethylamine to give the identifier, which can then be used without further purification.
  • the identifier can be obtained in high yield with no chloromethylketone byproduct. Also, purification by flash chromatography is no longer necessary, which in some cases has resulted in significant acid-catalyzed decomposition of the identifier.
  • the other 11 identifiers of Formula IV were prepared by analogous synthetic routes, steps (a), (b), and (c).
  • the 12 identifiers were used to encode the combinatorial library.
  • pentachlorophenyl identifiers where n 8-10
  • the acid (636 mg, 1.92 mmol, 1.5 equiv.) prepared above was dissolved in DMF (40 mL) and added to divinylbenzene-cross-linked, polyethyleneglycol-grafted polystyrene beads (TentaGel® S NH 2 , Rapp Polymere) (4.0 g, 0.32 mmol/g, 1.28 mmol, 1 equiv.) in a Merrifield reaction vessel. The resin was suspended by agitation, then HOBt (259 mg, 1.92 mmol, 1.5 equiv.) and DIC (0.31 mL, 1.92 mmol, 1.5 equiv.) were added in that order. The resin was agitated at room temperature for 7 hours at which time it gave a negative Kaiser test. The resin was filtered and washed (DMF 3 ⁇ 50 mL, DCM 3 ⁇ 50 mL) then dried in vacuo.
  • DMF divinylbenzene-cross-linked, polyethyleneglycol-
  • the two other dihydroxyacetophenones were attached to the resin via the photocleavable linker in an analogous manner using the reagents of Table 1-1.
  • Rhodium trifluoroacetate dimer (1 mL of a 1 mg/mL solution in DCM) was added to each of the vessels and the resin was agitated at room temperature for 4 hours. Each batch of resin was then filtered and washed with DCM (2 ⁇ 20 mL) then each was resuspended in DCM (20 mL) and treated a second time with the appropriate binary encoding mixture as described above. The resin was again agitated for 30 mins before addition of the rhodium triflouroacetate dimer. The same quantities of catalyst and diazoketone compounds were used in the second coupling step as in the first. The resin was agitated for 14 hours. Each resin batch was then washed with DCM (5 ⁇ 20 mL) then the batches were combined and the entire library (three compounds) was washed with DCM (10 ⁇ 50 mL).
  • the dried resin from Step 1(b) was divided into four batches of 1.5 g (c ⁇ . 0.42 mmol) and three additional batches of 0.2g (c ⁇ . 0.056 mmol).
  • the 1.5g batches were placed into 25 mL round-bottomed flasks and the 0.2 g batches were placed into 5 mL round-bottomed flasks.
  • the portions of resin were suspended in methanol (15 mL in the four flasks with 1.5 g of resin, 2 mL in the three flasks with 0.2 g of resin) and pyrrolidine (0.6 mL, 7.2 mmol, c ⁇ . 15 equiv.
  • Each batch of resin from Step 2(a) was placed into a separate synthesis vessel and was suspended in DCM (5 mL for the batches of 1.5 g of resin, 1 mL for the batches containing 0.2 g of resin).
  • the seven appropriate binary coding mixtures (see Table 1-2) for each batch of resin were prepared by dissolving the appropriate choice (22.5 mg if added to a batch of 1.5 g of resin; 3.0 mg if added to a batch of 0.2 g of resin) or choices (22.5 mg of each if added to a batch of 1.5 g of resin; 3.0 mg of each if added to a batch of 0.2 g of resin) of C 10 Cl 5 , C 9 Cl 5 , and C 8 Cl 5 linker-diazoketone (Preparation 1) in DCM (1 mL for each solution). These solutions were added to the appropriate synthesis vessel and the resin was agitated for 30 mins.
  • Rhodium trifluoroacetate dimer (1 mL of a 1 mg/mL solution in DCM) was added to each of the vessels and the resin was agitated at room temperature for 4 hr. Each batch of resin was then filtered and washed with DCM (2 ⁇ 20 mL) then each was resuspended in DCM (5 mL for the batches of 1.5 g of resin, 1 mL for the batches of 0.2 g of resin) and treated a second time with the appropriate binary encoding mixture as described above. The resin was again agitated for thirty mins before addition of the rhodium trifluoroacetate dimer.
  • Rhodium trifluoroacetate dimer (1 mL of a 1 mg/mL solution in DCM) was added to each of the vessels and the resin was agitated at room temperature for 4 hr. The supernatant solution was then decanted away from the resin with a Pasteur pipette. The resin was washed twice with DCM (3 mL) and the washings removed by Pasteur pipette. Each batch of resin was resuspended in DCM (2 mL) and treated a second time with the appropriate binary encoding mixture as described above. The resin was again agitated for thirty minutes before addition of the rhodium trifluoroacetate dimer.
  • chloroformates were prepared from the appropriate alcohols by treating the alcohols (0.1 g) with a solution of phosgene in toluene (5 mL of a 1.8 M solution) for 1 hr, then evaporating to dryness in vacuo ,and then redissolving in DCM (5 mL).
  • the flasks were filtered and the resin washed with DCM (3 ⁇ 10 mL). All of the resin was combined in one large synthesis vessel and was washed with DCM (3 ⁇ 50 mL), DMF (3 ⁇ 50 mL), and DCM again (3 ⁇ 50 mL). The resin was dried in vacuo.
  • the remaining 900 mg of resin from the four combined batches of 1.5 g from Step 2(b) which had not been used in Step 3 was divided into ten portions of 90 mg, and each portion placed in a separate 1 dram shell vial (Fisher Scientific).
  • the ten appropriate binary coding mixtures (see Table 1-5) for each batch of resin were prepared by dissolving the appropriate choice (1.5 mg) or choices (1.5 mg each) of C 7 Cl 5 , C 5 Cl 5 , C 4 Cl 5 , and C 3 Cl 5 linker-diazoketone (Preparation 1) in DCM (1 mL for each solution). These solutions were added to the appropriate synthesis vessels and the resin was agitated for 30 min.
  • Rhodium trifluoroacetate dimer (1 mL of a 1 mg/mL solution in DCM) was added to each of the vessels and the resin was agitated at room temperature for 4 hr. The supernatant solution was then decanted from the resin. The resin was washed (DCM 2 ⁇ 3 mL) and the washings removed by Pasteur pipette. The resin was then treated a second time with solutions of the appropriate binary coding mixtures and agitated for 30 min. before the addition of the rhodium trifluoroacetate dimer. The same quantities of catalyst and diazoketone compounds were used in the second coupling as in the first. The batches of resin were then agitated for 16 hr. The resin was then transferred into small Merrifield synthesis vessels and washed (DCM 6 ⁇ 15 mL). b) Deprotection.
  • Each batch of resin was treated with a solution of TFA in DCM (4 mL:4 mL). The resin was agitated for 1 hr, then filtered and washed with DCM (2 ⁇ 15 mL). The resin was then treated with a solution of piperidine in DCM (4 mL:4 mL) and agitated for 15 min. This treatment was repeated once. Each batch of beads was washed with methanol (2 ⁇ 15 mL) ana DCM (4 ⁇ 15 mL). Flasks 1-4 were washed with THF (3 ⁇ 15 mL).
  • Flasks 1-3 were then treated wi ⁇ i DBU (190 ⁇ L, c ⁇ . 40 equiv.) followed by the appropriate heteroaryl chloride (c ⁇ . 20 equiv.). Flasks 1 and 2 were heated at 55 °C for 16 hr. Flask 3 was heated at reflux for 16 hr. Flask 4 was treated with triethylamine (700 ⁇ L) and the appropriate heteroaryl chloride (c ⁇ . 20 equiv.). The resin was shaken at r.t. for 16 hr. Each batch of resin was then washed in THF (2 ⁇ 15 mL) and dried in vacuo.
  • THF 2 ⁇ 15 mL
  • the resin in flasks 5-10 was suspended in DMF (8 mL) and the appropriate aldehyde (c ⁇ . 67 equiv.) added. Acetic acid (160 ⁇ L) was added to each of the flasks followed by sodium cyanoborohydride (c ⁇ . 67 equiv.). Flasks 5, 6, 7, 9, and 10 were shaken at r.t. for 16 hr. Flask 8 was heated to 55 °C for 16 hr. Each batch of resin was filtered and washed with DMF (3 ⁇ 15 mL). Each of the reductive alkylation reactions was repeated under the same conditions.
  • the batches of resin were washed with DMF (2 ⁇ 15 mL), methanol (3 ⁇ 15 mL), and DCM (3 ⁇ 15 mL). The resin was then mixed, washed with DCM (2 ⁇ 20 mL), and dried in vacuo.
  • Rhodium trifluoroacetate dimer (1 mL of a 1 mg/mL solution in DCM) was added to each of the vessels and the resin was agitated at room temperature for 4 hr. Each batch of resin was then filtered and washed with DCM (2 ⁇ 20 mL) then each was resuspended in DCM (10 mL) and treated a second time with the appropriate binary encoding mixture as described above. The resin was again agitated for 30 mins before addition of the rhodium trifluoroacetate dimer. The same quantities of catalyst and diazoketone compounds were used in the second coupling step as in the first. The resin was agitated for 14 hr.
  • the resin in flask 2 was suspended in methanol (5 mL) and solid sodium borohydride (200 mg) was added cautiously. The flask was vented and allowed to shake gently for 1 hr. The resin was filtered and resuspended in methanol and the reduction process repeated a total of 5 times at 1 hr intervals using 200 mg of sodium borohydride each time. After the final cycle the resin was washed with methanol (3 ⁇ 20 mL) and DCM (3 ⁇ 20 mL).
  • a bead was placed in a 1.3 mm diameter pyrex capillary with 2 ⁇ L of acetonitrile. Ceric ammonium nitrate solution (2 ⁇ L of a 0.1 M aq.. solution) and hexane (3 ⁇ L) were added and the two-phase mixture centrifuged briefly. The tube was sealed and left at 35 °C for 16 hrs, then opened. The organic layer was removed by syringe and mixed with 1 ⁇ L of N,O-bis(trimethylsilyl)acetamide. The silated tag solution (1 ⁇ L) was analyzed by GC with electron capture (EC) detection.
  • EC electron capture
  • the GC analysis was performed with a Hewlett Packard 5890 plus gas chromatograph. On column injection into a 5 m, 0.32 mm retention gap connected to a 25 m, 0.2 mm crosslinked 5% phenylmethyl silicone column was used.
  • the temperature program was set at 200 °C for 1 min and then increased at a rate of 15°C/min from 200-320 °C.
  • the pressure program was set at 20 psi for 1 min, then increased at 2 psi/min to 40 psi with a total run time of 10 min.
  • the EC detector was maintained at 400 °C and the auxiliary gas was set at 35 psi.
  • the six batches of encoded resin are combined in a 2 L Erlenmeyer flask along with THF (1 L) and mixed thoroughly by swirling and stirring gently with a glass rod. The resin is then recovered by filtration and vacuum dried.
  • the mixed resin from Step 2 is divided into three batches of 14.4 g (c ⁇ . 8.1 mmol) and seven additional batches of 1.5 g (c ⁇ . 0.84 mmol).
  • the 14.4 g batches are placed into 250 mL round bottom flasks and the 1.5 g batches are placed in 25 mL round bottom flasks.
  • the portions of resin are suspended in methanol (150 mL in the three flasks with 14.4 g resin, 15 mL in the seven flasks with 1.5 g resin) and pyrrolidine (10.1 mL, 121 mmol, c ⁇ . 15 equiv. in the flasks with 14.4 g resin; 1.0 mL, 12.6 mmol, c ⁇ . 15 equiv.
  • Step 4 500 mL Erlenmeyer flask along with THF (250 mL) and mixed thoroughly by swirling and stirring gently with a glass rod. The resin is then recovered by filtration and vacuum dried. This combined resin is kept separate from the three 14.4 g batches of resin and is not subjected to the reaction conditions of Step 4, but rather re-divided into three 0.2 g portions and seven 1.4 g portions and saved to be used in Step 5 and alternate Step 5. The three 14.4 g batches of encoded resin are combined in a 2 L Erlenmeyer flask along with THF (1 L) and mixed thoroughly by swirling and stirring gently with a glass rod. The resin is then recovered by filtration, vacuum dried, and used in Step 4.
  • cyanoborohydnde (c ⁇ . 50 equiv.) is added and the resin agitated for 16 hr.
  • the resin is washed with alternating DCM and methanol (5X each) and then with EtOAc (2X).
  • the resin from the sixth of the seven 250 mL synthesis vessels containing deprotected resin from Step 4(a) (6 g, c ⁇ . 3.4 mmol) is transferred to a 250 mL round bottom flask. THF (150 mL) is added followed by DBU (c ⁇ . 40 equiv.). 2-Chloropyrimidine (c ⁇ . 20 equiv.) is added. The mixture is heated to 55°C for 16 hr. The resin is transferred back to a 250 mL synthesis vessel, washed with alternating DCM and methanol (5X each), and then with EtOAc (2X).
  • Each of the seven batches of resin from Step 4(b) are binariiy encoded in a fashion analogous to that described for the encoding of Step 1.
  • the seven encoded 5.7 g. batches of resin from Step 5(a) are placed in 200 mL round bottom flasks.
  • the seven encoded 1.4 g. batches from Step 3(c) are placed in 50 mL round bottom flasks.
  • To each of the fourteen flasks is added a solution of 10% glacial acetic acid in methanol (60 mL in the 200 mL flasks, 15 mL in the 50 mL flasks).
  • the appropriate amine from Table 2-6 (c ⁇ . 40 equiv.) is added followed by sodium cyanoborohydride (c ⁇ . 40 equiv.).
  • Condensers are attached and the mixtures are heated to 75°C for 48 hr.
  • the resin is washed with alternating DCM and methanol (5X each) and then with EtOAc (2X).
  • Step 6(a) total of c ⁇ . 32.5 g. is divided into ten 3.2 g.
  • N,N'-bis Boc-(L)-lysine (c ⁇ . 10 equiv.) as a solution in DMF (60 mL in the larger vessel, 15 mL in the smaller).
  • HOBt (c ⁇ . 15 equiv.) is added and the resin agitated for 15 min.
  • DIC (c ⁇ . 10 equiv.) is added and the resin agitated for 4 hr.
  • the resin is washed with DCM (2X) and then treated with TFA (30% solution in DCM) (1.5 hrs.).
  • the resin is then washed with DCM (2X) and treated with 10% triethylamine in DMF (2X, 30 min. each).
  • the resin is washed with alternating DCM and methanol (5X each) and then with EtOAc (2X).
  • N- ⁇ -Fmoc-N- ⁇ -Pmc-(L)-arginine (c ⁇ . 10 equiv.) as a solution in DMF (60 mL in the larger vessel, 15 mL in the smaller).
  • HOBt (c ⁇ .. 15 equiv.) is added and the resin agitated for 15 min..
  • DIC (c ⁇ . 10 equiv.) is added and the resin agitated for 4 hr.
  • the resin is washed with DCM (2X) and then treated with TFA (50% solution in DCM) (1.5 hrs.).
  • the resin is then washed with DCM (2X) and treated with 50% piperidine in DMF (2X, 30 min. each).
  • the resin is washed with alternating DCM and methanol (5X each) and then with EtOAc (2X).

Abstract

Combinatorial libraries are disclosed which are represented by the Formula (I): (T'-L)q- S -C(O)-L'-II' wherein S is a solid support; T'-L- is an identifier residue; and -L'-II' is a ligand/linker residue. These libraries contain dihydrobenzopyrans of formula (II) which interact (i.e., as agonists or antagonists) with α adrenergic receptors, dopamine receptor, σ-opiate receptors, and K+ channels and are inhibitors of carbonic anhydrase isozymes. They are useful in the treatment of ocular diseases such as glaucoma.

Description

TITLE OF THE INVENTION
COMBINATORIAL DIHYDRGBENZOPYRAN LIBRARY
BACKGROUND OF THE INVENTION
There is interest in methods for the synthesis of large numbers of diverse compounds which can be screened for various possible physiological or other activities. Techniques have been developed in which one adds individual units sequentially as part of the chemical synthesis to produce all or a substantial number of the possible compounds which can result from all the different choices possible at each sequential stage of the synthesis. For these techniques to be successful, it is necessary for the compounds to be amenable to methods by which one can determine the structure of the compounds so made. Brenner and Lerner (PNAS USA 81: 5381-83 (1992)) and WO
93/20242, for example, describe a synthesis wherein oligonucleotides are produced in parallel with and are chemically linked as genetic tags to oligopeptides as the compounds of interest. WO 93/06121 teaches methods for particle-based synthesis of random oligomers wherein identification tags on the particles are used to facilitate identification of the oligomer sequence synthesized. A detachable tagging system is described in Ohlmeyer et al., Proc. Natl. Acad. Sci. USA, 90, 10922- 10926, Dec. 1993.
SUMMARY OF THE INVENTION
The present invention relates to combinatorial chemical libraries of compounds encoded with tags and to the use of these libraries in assays to discover biologically active compounds. The present invention also relates to libraries containing
dihydrobenzopyrans and using these libraries to identify biologically active members by screening for inhibition of carbonic anhydrase isozymes. The present invention also relates to members of the library which interact (i.e., as agonists or antagonists) with α adrenergic receptors, dopamine receptors, σ-opiate receptors, and K+ channels. In particular, the present invention also relates to members of the library which are inhibitors of carbonic anhydrase. The invention also relates to methods for their preparation, intermediates, and to methods and pharmaceutical formulations for using these dihydrobenzopyrans in the treatment of mammals, especially humans. Because of their activity as inhibitors of carbonic anhydrase isozymes, compounds of the present invention are useful in the treatment of such diseases as glaucoma.
DETAILED DESCRIPTION OF THE INVENTION
The combinatorial libraries of the present invention are represented by Formula I:
(T'-L)q-ⓢ -C(O)-L'-II' I
wherein: ⓢ is a solid support;
T'-L- is an identifier residue;
-L'-II' is a ligand/linker residue; and
q is 3-30.
Preferred compounds of Formula I are those wherein:
T'-L- is of the Formula:
Figure imgf000004_0001
wherein n = 3-12 when Ar is pentachlorophenyl and
n = 3-6 when Ar is 2,4,6-trichlorophenyl;
q is 4-12; and -L'- is
or
Figure imgf000005_0001
Figure imgf000005_0002
wherein the left-hand bond as shown is the point of attachment to the solid support and the right hand bond is the point of attachment to the ligand, and B is O or N(CH2)1-6R17, with the proviso that in (b) when B is N(CH2)1-6R17' the ligand is attached to B through a carbonyl group.
Other preferred compounds of Formula I are those of Formulae la, lb, or Ic wherein -C(O)-L'-II' is:
Figure imgf000005_0003
Figure imgf000005_0004
or
Figure imgf000005_0005
Depending on the choice of L' (see Table 1), the ligands of Formula II may be detached by photolytic, oxidative, or other cleavage techniques. For example, when -L'- is (b) and B is O (or
N(CH2) 1-6R17), photolytic detachment may be represented by:
Figure imgf000006_0003
or
+ II'NH(CH2)1-6R17 (B = N(CH2) 1 -6R17) wherein L" is the residue from L' and II'OH (or H'NH(CH2) 1-6R17)is II.
Therefore, compounds of the present invention are also represented by Formula II
Figure imgf000006_0001
wherein:
R1 is OH, O(CH2) 1-2OH, OCH2CO2H, CO2H,
O-Z-C(O)NH(CH2) 1-6R17, or
OCH2-4-Phe-C(O)NH(CH2)1-6R17;
R2 is H or lower alkyl;
R3 is H, alkyl, aryl, or arylalkyl;
R4 and R5 is each independently H, lower alkyl, or substituted lower alkyl where the substituents are 1-3 alkoxy, aryl, substituted aryl, carboalkoxy, carboxamido, or diloweralkylamido; or R4 and R5 taken together are
-(CH2)n-- , -(CH2)2-O-(CH2)2-, -CH2-O-(CH2)3-.
-(CH2)2-NR8-(CH2)2-, -CH2-NR8-(CH2)m-, -(CH2)2CH(NHR8)(CH2)2-, -(CH2)2-S(O)0-2-(CH2)2- , or
;
Figure imgf000006_0002
one of R6 and R7 is H and the other is H, OH, or N(CH2) 1-6R14R15; or R6 and R7 taken together are ,
Figure imgf000007_0002
Figure imgf000007_0003
,
Figure imgf000007_0004
, or ;
Figure imgf000007_0005
Figure imgf000007_0006
R8 is H, COOR9, CONHR10, CSNHR11, COR12, SO2R13, lower alkyl, aryl lower alkyl, heteroaryl, or heteroaryl lower alkyl, wherein aryl is optionally substituted with 1-3 substituents selected from lower alkyl, lower alkoxy, halo, CN, NH2, COOH, CONH2, carboalkoxy, and mono- or di- lower alkylamino and wherein heteroaryl is a mono- or bicyclic heteroaromatic ring system of 5 to 10 members including 1 to 3 heteroatoms selected from O, N, and S and 0-3 substituents selected from halo, amino, cyano, lower alkyl, carboalkoxy, CONH2, and S-lower alkyl;
R9 is lower alkyl, aryl, aryl lower alkyl, heteroaryl, aryl
substituted by 1-3 substituents selected from alkyl, alkenyl, alkoxy, methylene dioxy, and halo, or a 5 to 6-membered heterocyclic ring wherein the hetero atom is O or N, wherein heteroaryl is a heteroaromatic ring of 5 to 6 members including 1 to 2 heteroatoms selected from O, N, and S and 0-2 substituents selected from lower alkyl, dialkylamino, lower alkoxy, and halo;
R10 and R11 is each independently lower alkyl, aryl, aryl lower alkyl, or aryl substituted by 1-3 substituents selected from lower alkyl, halo, alkoxy, and haloalkyl;
R12 is lower alkyl, aryl, heteroaryl, aryl lower alkyl,
heteroaryl lower alkyl, a 5- or 6-membered heterocyclic ring containing 1-2 heteroatoms selected from O, S, and N, a 5- or 6-membered heterocyclic ring containing 1-2 heteroatoms selected from O, S, and N lower alkyl, or aryl substituted with 1-3 substituents selected from lower alkyl, alkoxy, halo, sulfamoyl, lower alkyl sulfamoyl, cyano, and phenyl;
R13 is lower alkyl, aryl, or aryl substituted with 1-3 substituents selected from lower alkyl, alkoxy, halo, CN, and haloalkyl; R14 is H; alkyl substituted by 1-3 alkoxy, S-loweralkyl,
sulfamoyl, halo, alkylsulphonamido, or arylsulphonamido; alkenyl; alkynyl; aryl; substituted aryl; heteroaryl;
substituted heteroaryl; heterocycloalkyl;
-CH2NR16C(O)R16; -C(O)NR16R16; -CH2OC(O)R16; or -CH2SC(O)R16;
R15 is H, alkyl, -C(O)X, -C(S)X, or -C(NCN)NR3R3;
R16 is lower alkyl, substituted lower alkyl, aryl, or substituted aryl;
R17 is H; alkyl substituted by 1-3 alkoxy, S-loweralkyl,
sulfamoyl, halo, alkylsulphonamido, or arylsulphonamido; alkenyl; alkynyl; aryl; substituted aryl; heteroaryl;
substituted heteroaryl; heterocycloalkyl;
-CH2NR16C(O)R16; -C(O)NR16R16; -CH2OC(O)R16; or
-CH2SC(O)R16;
X is alkyl, aryl, arylalkyl, O-loweralkyl, or NR3R3
Z is -(CH2) 1-6-, optionally substituted with 1-3 lower alkyl;
CHR2; Phe-CH2-, where Phe is optionally mono- substituted with halogen, lower alkyl, or alkoxy; or heteroary lene-(CH2)-;
m is 2 or 3;
n is 4-9;
or a pharmaceutically acceptable salt thereof.
Preferred compounds of Formula II are those wherein R12 is sulfamoylphenyl, most preferably p-sulfamoylphenyl. A preferred embodiment of the invention is a compound of
Formula II wherein:
R1 is OH, OCH2C(O)NH(CH2) 1-6R14, or OCH2-4-Phe- C(O)NH(CH2) 1-6R14;
R2 is H or lower alkyl; R4 and R5 is each lower alkyl; or R4 and R5 taken together are
-(CH2)5-, -(CH2)2-O-(CH2)2-, -(CH2)2.NR8-(CH2)2-, -(CH2)2-CH(NHR8)(CH2)2-, -(CH2)2-S-(CH2)2- , or
;
Figure imgf000009_0001
R6/R7 are H/OH, =O, or -S(CH2)2S-;
R8 is H, COOR9, CONHR10, CSNHR11, COR12, SO2R13, .
lower alkyl, aryl lower alkyl, heteroaryl wherein the ring members include 1 to 3 N atoms and the substituents are halo or amino, heteroaryl lower alkyl wherein heteroaryl is 6-membered and the heteroatoms are N, or aryl lower alkyl substituted with 1 substituent selected from lower alkyl, alkoxy, and halo;
R9 is lower alkyl, aryl lower alkyl, aryl, tetrahydrofuranyl, tetrahydropyranyl, or aryl substituted by 1 to 2 substituents selected from lower alkyl, alkenyl, alkoxy, methylene dioxy, and halo;
R10 and R11 is each independently aryl, aryl lower alkyl, or aryl
substituted by 1 substituent selected from lower alkyl, halo, alkoxy, trifluoromethyl, and pentafiuoroethyl; R12 is lower alkyl, aryl, aryl lower alkyl, heteroaryl lower alkyl wherein the heteroatoms are N, a 5- or 6-membered heterocyclic ring containing 1-2 heteroatoms selected from S and N lower alkyl, or aryl substituted with 1 substituent selected from lower alkyl, alkoxy, halo, sulfamoyl, cyano, or phenyl;
R13 is lower alkyl, aryl, or aryl substituted with 1 substituent selected from lower alkyl, alkoxy, and halo; or a pharmaceutically acceptable salt thereof. Most preferred compounds of the invention are represented by the formula:
Figure imgf000010_0001
wherein:
R1 is 6- or 7-OH;
R2 is H or lower alkyl;
R4 and R5 is each methyl; or R4 and R5 taken together are -(CH2)5-,
-(CH2)2-O-(CH2)2-, -(CH2)2-NR8-(CH2)2-,
-CH2-NR8-(CH2)3-, -CH2-NR8-(CH2)2-, or
-(CH2)2-CH(NHR8)(CH2)2-;
one of R6 and R7 is H and the other is OH or R6 and R7 taken together are =O or -S(CH2)2S-;
R8 i is H, COOR9, CONHR10, CSNHR1 1, COR12, SO2R13, benzyl, -CH2-Ph-4-F, -CH2-Ph-4-OCH3, -CH2-4-Py, n-butyl, -CH2-c-propyl, , or
Figure imgf000010_0002
Figure imgf000010_0008
Figure imgf000010_0007
Figure imgf000010_0003
; R9 is i-propyl, phenyl, phenethyl, t-butyl,
, or
Figure imgf000010_0004
Figure imgf000010_0006
Figure imgf000010_0005
;
R10 is phenyl, p-chlorophenyl, or p-trifluoromethylphenyl;
R11 is phenyl, benzyl, or 1-naphthyl; R12 is
Figure imgf000011_0002
,
Figure imgf000011_0003
, ,
Figure imgf000011_0004
Figure imgf000011_0005
, ,
Figure imgf000011_0008
,
Figure imgf000011_0006
Figure imgf000011_0007
Figure imgf000011_0009
, or
Figure imgf000011_0010
; and
R13 is 1- or 2-naphthyl, phenyl, 4-chlorophenyl, 4- methylphenyl, 4-t-butylphenyl, n-butyl, or i-propyl;
or a pharmaceutically acceptable salt thereof.
Most preferred compounds of the invention are also represented by the formula:
Figure imgf000011_0001
wherein
R 1 is 6- or 7-OH when R2 is H;
R1 is 7-OH when R2 is CH3;
R4 and R5 is each methyl; or R4 and R5 taken together are -(CH2)5-,
-(CH2)2-O-(CH2)2-, -(CH2)2-NR8-(CH2)2-,
-CH2-NR8-(CH2)3-, -CH2-NR8-(CH2)2-, or -(CH2)2- CH(NHR8)(CH2)2-;
one of R6 and R7 is H and the other is OH or R6 and R7 taken together are =0 or -S(CH2)2S-; and
R8 is
Figure imgf000012_0001
Figure imgf000013_0001
Most preferred compounds of the invention are represented by the formula:
Figure imgf000014_0001
wherein:
R1 is 6- or 7-OCH2C(O)NH(CH2) 1-6R17, or 6- or 7-OCH2-4- Phe-C(O)NH(CH2)1-6R17 when R2 is H;
R1 is 7-OCH2C(O)NH(CH2) 1-6R17, or 7-OCH2-4-Phe- C(O)NH(CH2) 1-6R17 when R2 is CH3;
R4 and R5 is each methyl; or R4 and R5 taken together are -(CH2)5-,
-(CH2)2-O-(CH2)2-, -(CH2)2-NR8-(CH2)2-,
-(CH2)2-CH(NHR8)(CH2)2-, -(CH2)2-S-(CH2)2- , or
;
Figure imgf000014_0002
or R4 is methyl and R5 is CH2OCH3 or -(CH2)3N(Et)2; one of R6 and R7 is H and the other is OH; or R6 and R7 taken together are =O or -S(CH2)2S-; or one of R6 and R7 is H and the other is NAB, where A is methyl, 2-methoxyethyl,
2-phenylethyl, 4-methoxybenzyl, 2-tetrahydrofuranylmethyl, 2(3,4-dimethoxyphenyl)ethyl, or
2,2-diphenylethyl and B is
H, -SO2CH3 , , ,
Figure imgf000014_0003
Figure imgf000014_0004
, ,
Figure imgf000014_0006
Figure imgf000014_0005
, ,
Figure imgf000015_0001
Figure imgf000015_0002
Figure imgf000015_0003
Figure imgf000015_0004
, or
Figure imgf000015_0005
. R8 is H, CONHCH3, SO2Ph, (CH2)3CH3, CO(CH2)2CH3, benzyl, -C(O)-(4-Phe)-SO2NH2, or
Figure imgf000015_0006
; R 13 is
H, -SO2CH3 , , ,
Figure imgf000015_0007
Figure imgf000015_0008
, ,
Figure imgf000015_0010
Figure imgf000015_0009
, ,
Figure imgf000015_0011
.
Figure imgf000015_0012
Figure imgf000015_0013
Figure imgf000015_0015
, or
Figure imgf000015_0014
; (CH2) 1-6R14 is methyl, n-butyl, 3-methoxy-n-propyl, CH2-c-propyl, or
-(CH2)1-3-phenyl; and
(CH2)1-6R17 is methyl, 2-methoxyethyl, 2-phenylethyl,
4-methoxybenzyl, methyl-2-tetrahydrofuranyl,
2(3,4-dimethoxyphenyl)ethyl, or 2,2-diphenylethyl;
or a pharmaceutically acceptable salt thereof. Especially preferred, as inhibitors of carbonic anhydrase, are compounds of formulae IIb, IIc, and IId:
Figure imgf000016_0001
Figure imgf000016_0003
Figure imgf000016_0002
wherein:
R1 is 6- or 7-OH, 6- or 7-OCH2C(O)NH(CH2) 1-6R17, or
6- or 7-OCH2-4-Phe-C(O)NH(CH2) 1-6R17;
R2 is H or CH3;
R8 is -CO-Ph-p-SO2NH2; and
R6 and R7 together are =O or -SCH2CH2S-.
Most preferred of these are the following compounds:
Figure imgf000016_0004
R14 and R17 may each be any pharmacologically relevent orgaic radical, such as those derived by removal of H2NCH2- from the following compounds:
Figure imgf000017_0001
Figure imgf000018_0001
Figure imgf000019_0001
Figure imgf000020_0001
Figure imgf000021_0001
Figure imgf000022_0001
Figure imgf000023_0001
Figure imgf000024_0001
Figure imgf000025_0001
Figure imgf000026_0001
Figure imgf000027_0001
Figure imgf000028_0001
Figure imgf000029_0001
Figure imgf000030_0001
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000038_0001
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
Figure imgf000042_0001
Figure imgf000043_0001
Figure imgf000044_0001
Figure imgf000045_0001
Figure imgf000046_0001
Figure imgf000047_0001
Figure imgf000048_0001
Figure imgf000049_0001
Figure imgf000050_0001
Figure imgf000051_0001
Figure imgf000052_0001
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000056_0001
One embodiment of the invention is the use of the
combinatorial library of Formula I in assays to discover biologically active compounds (ligands) of Formula II. Thus, an aspect of the invention is a method of identifying a compound having a desired characteristic which comprises synthesizing a combinatorial library of Formula I and testing the compounds of Formula I and the ligands of Formula II, either attached to the solid support or detached therefrom, in an assay which identifies compounds having the desired
characteristic. A further embodiment of the invention is determining the structure of any compound so identified.
Another embodiment of the invention is a process for preparing a compound of the formula:
Figure imgf000057_0001
where R2 is H or lower alkyl;
which comprises a) reacting allyl or methyl 4-(hydroxymethyl)-3-nitrobenzoate with a compound of the formula:
Figure imgf000057_0002
in the presence of triphenylphosphine, toluene, and DEAD and stirring the mixture at room temperature to produce
Figure imgf000057_0003
where R is allyl or methyl and b) when R is allyl reacting said compound with methylene chloride, tetrakistriphenylphosphine palladium(0), and pyrrol idine and stirring the mixture at 0°C, or when R is methyl reacting said compound with dilute NaOH and THF and stirring the mixture at 0°C.
For this reaction, R=allyl is preferable to the t-butyl or methyl esters since the milder conditions would not induce aldol type condensation of the acetophenone portion of the molecule.
Another embodiment of the invention is a method for identifying compounds that are inhibitors of carbonic anhydrase which comprises preparing a mixture of 20-300 pmol test compound and aqueous solutions (total volume: 25-100, preferably about 50, μL) of 0.03-0.12, preferably about 0.06, μM carbonic anhydrase and 0.04- 0.16, preferably about 0.08, μM dansylamide, exposing said mixture to U.V. (preferably 274 nm) light, and determining the amount of emitted U.V. (preferably 454 nm) light.
Another embodiment of the invention is a method for identifying compounds that are enzyme inhibitors which is a lawn assay which comprises contacting a colloidal matrix containing enzyme, which matrix has embedded therein a mono-layer of solid supports with attached ligands, with a layer of fluorogenic substrate-containing material, eluting said ligands by exposure to U.V. light, and detecting zones of inhibition in the colloidal matrix produced thereby. A preferred such lawn assay comprises contacting an agarose matrix containing bovine carbonic anhydrase with a fluorescein diacetate-containing layer of agarose.
Another embodiment of the invention is a compound of the formula:
Figure imgf000058_0001
wherein: ⓢ is a solid support;
R is H or alkyl;
R16 is lower alkyl, substituted lower alkyl, aryl, or substituted aryl;
R17 is H; alkyl substituted by 1-3 alkoxy, S-loweralkyl,
sulfamoyl, halo, alkylsulphonamido, or arylsulphonamido; alkenyl; alkynyl; aryl; substituted aryl; heteroaryl;
substituted heteroaryl; heterocycloalkyl;
-CH2NR16C(O)R16; -C(O)NR16R16; -CH2OC(O)R16; or
-CH2SC(O)R16; and
Y is aryl or heteroaryl.
Compounds of formula 14 are useful as intermediates in the construction of combinatorial libraries and are especially useful in automated or batch mode syntheses thereof.
Definitions
The following abbreviations have the indicated mean:
Boc = t-butyloxycarbonyl
c- = cyclo
DEAD = diethylazodicarboxylate
DBU = 1,8-diazabicyclo[5,4,0]undec-7-ene
DCM = dichloromethane = methylene chloride
DIC = diisopropylcarbodiimide
DMAP = 4-N,N-dimethyIaminopyridine
DMF = N,N-dimethylformamide
DMSO = dimethyl sulfoxide
DVB = 1,4-divinylbenzene
EDT = 1,2-ethanedithiol
equiv. = equivalent
Et = ethyl
FACS = fluorescence activated cell sorting
Fmoc = 9-fluorenylmethoxycarbonyl
GC = gas chromatography
HOBt = N-hydroxybenzotriazole
hr = hour, hours im = imidazole
in = indole
m- = meta
Me = methyl
Mtr = 4-methoxy-2,3,6-trimethylbenzenesulfonyl n- = normal
Naph = naphthyl
p- = para
PEG = polyethylene glycol
Ph = phenyl
Phe = phenylene
Pmc = 2,2,5,7,8-pentamethylchroman-6-sulfamoyl
Py = pyridyl
r.t. = room temperature
sat'd = saturated
s- = secondary
t- = tertiary
t-Boc = t-butyloxycarbonyl
TFA = trifluoroacetic acid
THF = tetrahydrofuran
"Alkyl" is intended to include linear, branched, or cyclic structures and combinations thereof of from 1 to 20 carbon atoms. "Lower alkyl" includes alkyl groups of from 1 to 8 carbon atoms.
Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s- and t-butyl, pentyl, hexyl, octyl, c-propyl, c-butyl and the like. "Lower cycloalkyl" includes cycloalkyl groups of from 3 to 8 carbon atoms. Examples of lower cycloalkyl groups include c-propyl, c-butyl, c-pentyl, 2-methylcyclopropyl, cyclopropylmethyl, and the like.
"Alkenyl" is C2-C6 alkenyl of a linear, branched, or cyclic
(C5-C6) configuration and combinations thereof. Examples of alkenyl groups include allyl, isopropenyl, pentenyl, hexenyl, c-hexenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, and the like.
"Alkynyl" is C2-C6 alkynyl of a linear, branched, or cyclic (C5-C6) configuration and combinations thereof. Examples of alkynyl groups include ethynyl, propargyl, 3-methyl-1-pentynyl, 2-heptynyl isopropynyl, pentynyl, hexynyl, c-hexynyl, 1-propynyl, 2-butynyl, 2-methyl-2-butynyl, and the like.
"Alkoxy" means alkoxy groups of from 1 to 6 carbon atoms of a straight, branched, or cyclic configuration. Examples of alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy, and the like.
"Substituted loweralkyl" means lower alkyl substituted with 1-3 alkoxy, carboalkoxy, carboxamido, di-loweralkylamino, aryl, substituted aryl, or heteroaryl.
"Aryl" means phenyl or naphthyl.
"Substituted aryl" means aryl substituted with 1-3 halo, loweralkyl, alkoxy, aryl, S-loweralkyl, alkylsulphonamido,
arylsulphonamido, or sulfamoyl.
"Heteroaryl" means a 5 or 6 membered aromatic ring containing 1-3 hetero atoms selected from O, N, and S.
"Substituted heteroaryl" means heteroaryl substituted with 1-3 halo, loweralkyl, alkoxy, aryl, S-loweralkyl, alkylsulphonamido, arylsulphonamido, or sulfamoyl.
"Heterocycloalky" means lower cycloalkyl containing 1-3 hetero atoms selected from O, N, and S.
Halogen includes F, Cl, Br, and I.
L and L' are depicted in Table 1 , which also shows cleavage reagents. In designing a synthetic scheme, L and L' are chosen such that they are orthogonally reactive; i.e., they must allow for removal of either T or II (where T = T'-OH) without removal of the other since simultaneous cleavage of both T and II from the solid support is disadvantageous. In the structures as shown, the left-hand bond is the point of attachment to the solid support and the right-hand bond is the point of attachment to either T or II.
Figure imgf000062_0001
The tags of this invention, T, are chemical entities which possess several properties: they must be detachable from the solid supports, preferably by photolysis or oxidation; they must be
individually differentiable, and preferably separable; they must be stable under the synthetic conditions; they must be capable of being detected at very low concentrations, e.g., 10-18 to 10-9 mole; they should be identifiable with readily-available equipment which does not require sophisticated technical capabilities to operate; and they should be relatively economical. The tags may be structurally related or unrelated, e.g., a homologous series, repetitive functional groups, related members of the Periodic Chart, different isotopes, combinations thereof, and the like. At the end of the combinatorial synthesis, to each solid support, there will usually be attached at least 0.01 femtomol, usually 0.001-50 pmol, of each tag. The tags may be aliphatic, alicyclic, aromatic, heterocyclic, or combinations thereof.
Distinguishing features may be the number of repetitive units, such as methylene groups in an alkyl moiety; alkyleneoxy groups in a
polyalkyleneoxy moiety; halo groups in a polyhalo compound; α-and/or β-substituted ethylene groups where the substituents may be alkyl groups, oxy, carboxy, amino, halo, or the like; isotopes; etc.
The materials upon which the combinatorial syntheses of the invention are performed are referred to as solid supports, beads, and resins. These terms are intended to include:
a) beads, pellets, disks, fibers, gels, or particles such as cellulose beads, controlled pore-glass beads, silica gels, polystyrene beads optionally cross-linked with divinylbenzene and optionally grafted with polyethylene glycol and optionally functionalized with amino, hydroxy, carboxy, or halo groups, grafted co-poly beads, polyacrylamide beads, latex beads, dimethylacrylamide beads optionally cross-linked with N,N'-bis-acryloyl ethylene diamine, glass particles coated with hydrophobic polymer, etc., i.e., material having a rigid or semi-rigid surface; and
b) soluble supports such as low molecular weight non-cross-linked polystyrene. It is intended that the definitions of any substituent or symbol (e.g., R3) in a particular molecule be independent of its definitions elsewhere in the molecule. Thus, NR3R3 represents NH2, NHCH3, N(CH3)2, etc. Optical Isomers - Diastereomers - Geometric Isomers - Tautomers
Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms which may be defined in terms of absolute stereochemistry as (R) or (S). The present invention is meant to comprehend all such possible diastereomers as well as their racemic and optically pure forms and mixtures thereof. Optically active (R) and (S) forms may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended to include both E and Z geometric isomers. Likewise, all tautomeric forms are intended to be included.
Salts
The pharmaceutical compositions of the present invention comprise a compound of Formula II as an active ingredient or a pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier and, optionally, other therapeutic ingredients. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic acids or bases including organic and inorganic acids or bases.
When a compound of the present invention is acidic, salts may be prepared from pharmaceutically acceptable non-toxic bases. Salts derived from all stable forms of inorganic bases include
aluminum, ammonium, calcium, copper, iron, lithium, magnesium, manganese, potassium, sodium, zinc, etc. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion-exchange resins such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine,
ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, isopropylamine, lysine, methylglucosamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, etc.
When a compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic, etc. Particularly preferred are citric, hydrobromic, maleic, phosphoric, sulfuric, and tartaric acids.
In the discussion of methods of treatment herein, reference to the compounds of Formula II is meant to also include the
pharmaceutically acceptable salts thereof.
Utilities
The ability of the compounds of Formula II to interact with α adrenergic receptors indicates that the compounds are useful to treat, prevent, or ameliorate hypertension and benign prostate hypertrophy in mammals, especially in humans.
The ability of the compounds of Formula II to interact with dopamine receptors indicates that the compounds are useful to treat, prevent, or ameliorate Alzheimer's disease and depression in humans.
The ability of the compounds of Formula II to interact with σ-opiate receptors indicates that the compounds are useful to treat, prevent, or ameliorate schizophrenia in mammals, especially in humans.
The ability of the compounds of Formula II to interact with
K+ channels indicates that the compounds are useful to treat, prevent, or ameliorate hypertension, asthma, and pulmonary insufficiency in mammals, especially in humans.
The ability of certain compounds of Formula II to inhibit carbonic anhydrase isozymes makes them useful for preventing or reversing the symptoms induced by these enzymes in a mammal. This enzyme inhibition indicates that the compounds are useful to treat, prevent, or ameliorate ocular diseases, particularly glaucoma in mammals, especially in humans.
Dose Ranges
The magnitude of the prophylactic or therapeutic dose of the compounds of Formula II will vary with the nature and severity of the condition to be treated and with the particular compound of
Formula II and its route of administration. In general, the daily dose range for anti-enzymic use lies in the range of 20 to 0.001 mg/kg body weight of a mammal, preferably 10 to 0.01 mg/kg, and most preferably 1.0 to 0.1 mg/kg, in single or divided doses. In some cases, it may be necessary to use doses outside these ranges.
When a composition for intravenous administration is employed, a suitable daily dosage range is from about 10 to 0.0005 mg (preferably 5 to 0.01 mg) compound of Formula II per kg body weight.
When a composition for oral administration is employed, a suitable daily dosage range is from about 20 to 0.001 mg (preferably 10 to 0.01 mg) compound of Formula II per kg body weight.
When a composition for ophthalmic administration is employed, a suitable daily dosage range is from about 10-0.01 %
(preferably 5.0-0.5% compound of Formula II, typically prepared as a 2.0-0.1 % by weight solution or suspension of a compound of Formula II in an acceptable ophthalmic formulation.
The compounds of Formula II may also be used in combination with other pharmaceutically active ingredients. For example, a typical ocular formulation may comprise the compound alone or in combination with a β-adrenergic blocking agent such as timolol maleate or a parasympathomimetic agent such as pilocarpine. When used in combination, the two active ingredients are present in approximately equal parts.
Pharmaceutical Compositions
Any suitable route of administration may be employed for providing a mammal, especially a human, with an effective dosage of a compound of Formula II. For example, oral, rectal, topical, parenteral, ocular, pulmonary, nasal, etc. routes may be employed. Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like.
The pharmaceutical compositions of the present invention comprise a compound of Formula II, or a pharmaceutically acceptable salt thereof, as an active ingredient, and may also contain a
pharmaceutically acceptable carrier and, optionally, other
therapeutically active ingredients.
The compositions include compositions suitable for oral, rectal, topical (including transdermal devices, aerosols, creams, ointments, lotions, and dusting powders), parenteral (including subcutaneous, intramuscular, and intravenous), ocular (ophthalmic), pulmonary (nasal or buccal inhalation), or nasal administration;
although the most suitable route in any given case will depend largely on the nature and severity of the condition being treated and on the nature of the active ingredient. They may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
A compound of Formula II may be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the nature of the preparation desired for administration, i.e., oral, parenteral, etc. In preparing oral dosage forms, any of the usual pharmaceutical media may be used, such as water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like in the case of oral liquid preparations (e.g., suspensions, elixirs, and solutions); or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, etc. in the case of oral solid preparations such as powders, capsules, and tablets. Solid oral preparations are preferred over liquid oral preparations. Because of their ease of administration, tablets and capsules are the preferred oral dosage unit form. If desired, capsules may be coated by standard aqueous or non-aqueous techniques.
In addition to the dosage forms described above, the compounds of Formula II may be administered by controlled release means and devices such as those described in U.S.P. Nos. 3,536,809; 3,598,123; 3,630,200; 3,845,770; 3,916,899; and 4,008,719, which are incorporated herein by reference.
Pharmaceutical compositions of the present invention suitable for oral administration may be prepared as discrete units such as capsules, cachets, or tablets each containing a predetermined amount of the active ingredient in powder or granular form or as a solution or suspension in an aqueous or nonaqueous liquid or in an oil-in-water or water-in-oil emulsion. Such compositions may be prepared by any of the methods known in the art of pharmacy. In general, the compositions are prepared by uniformly and intimately admixing the active
ingredient with liquid carriers, finely divided solid carriers, or both and then, if necessary, shaping the product into the desired form. For example, a tablet may be prepared by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as powder or granule optionally mixed with a binder, lubricant, inert diluent, or surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Ophthalmic inserts are made from compression molded films which are prepared on a Carver Press by subjecting the powdered mixture of active ingredient and HPC to a compression force of 12,000 lb. (gauge) at 149°C for 1-4 min. The film is cooled under pressure by having cold water circulate in the platen. The inserts are then
individually cut from the film with a rod-shaped punch. Each insert is placed in a vial, which is then placed in a humidity cabinet (88% relative humidity at 30°C) for 2-4 days. After removal from the cabinet, the vials are capped and then autoclaved at 121°C for 0.5 hr.
The following are representative pharmaceutical dosage forms of the compounds of Formula II: I.M. Injectable Suspension mg/mL
Compound of Formula II 10
Methylcellulose 5
Tween 80 0.5
Benzyl alcohol 9
Benzalkonium chloride 1
Water for injection to a total volume of 1 mL
Tablet mg/tablet
Compound of Formula II 25
Microcrystalline cellulose 415
Povidone 14
Pregelatinized starch 43.5
Magnesium stearate 2.5
500
Capsule mg/capsule
Compound of Formula II 25
Lactose powder 573.5 Magnesium stearate 1.5
600 Aerosol Per canister
Compound of Formula II 24 mg Lecithin, NF liquid concentrate 1.2 mg Trichlorofluoromethane, NF 4.025 gm Dichlorodifluoromethane, NF 12.15 gm Ophthalmic Solution mg/mL
Compound of Formula II 1
Monobasic sodium phosphate•2H2O 9.38
Dibasic sodium phosphate•12H2O 28.48 Benzalkonium chloride 1
Water for injection to a total volume of 1 mL
Ophthalmic Suspension mg/g
Compound of Formula II 1
Petrolatum liquid to a total weight of 1 g Ophthalmic Insert mg/insert
Compound of Formula II 1
Hydroxypropylcellulose 12
These compounds of Formulae I and II may also be used as libraries for discovering new lead structures by evaluation across an array of biological assays, including the discovery of selective inhibition patterns across isozymes. These libraries are thus tools for drug discovery; i.e., as a means to discover novel lead compounds by screening the libraries against a variety of biological targets and to develop structure-activity relationships in large families of related compounds. The libraries may be tested with the ligands attached to the solid supports as depicted in Formula I or the individual compounds II may be detached prior to evaluation. With the compounds of Formula I, screening assays such as FACS sorting, bead lawn assays, and cell lawn assays may be used. When a compound is detached prior to evaluation, its relationship to its solid support is maintained, for example, by location within the grid of a standard 96-well plate or by location of activity on a lawn of cells. The solid support associated with bioactivity or the solid support related to the detached ligand may then be decoded to reveal the structural or synthetic history of the active compound (Ohlmeyer et al., Proc. Natl. Acα.d. Sci. USA, 90, 10922-10926, Dec. 1993).
Assays for Determining Biological Activity
The compounds of the present invention may be tested by assays well known in the art for interaction with α adrenergic
receptors, interaction with dopamine receptors, interaction with σ-opiate receptors, interaction with K+ channels, and carbonic anhydrase inhibition. For example, representative references teaching carbonic anhydrase inhibition assays are: Carbonic Anhydrase Inhibition - Maren and Couto, "The
Nature of Anion Inhibition of Human Red Cell Carbonic Anhydrases", Archiv. of Biochem. and Biophy., 196, No. 2, Sept., 501-510 (1979). Carbonic Anhydrase Inhibition - Ponticello et al.,
"Thienothiopyran-2-sulfonamides: A Novel Class of Water-Soluble Carbonic Anhydrase Inhibitors", J. Med. Chem., 30, 591-597 (1987).
Carbonic Anhydrase Inhibition - It has now been found that the use of very low initial concentrations (0.04-1.6, preferably about 0.6, μM) of dansylamide and (0.03-1.2, preferably about 0.3, μM) of carbonic anhydrase to assay test compounds for carbonic anhydrase inhibition not only allows the use of very small total volumes (approx. 25-100, preferably about, 50 μL) per assay but also allows one to distinguish high-affinity from low-affinity compounds without either re-elution or re-synthesis of the test compound. By increasing the concentration of dansylamide from -0.1 μM to ~200 μM directly in the assay sample, relatively weak inhibitors can be distinguished from relatively strong inhibitors on the same aliquot of test compound. The small total volume advantageously permits high throughput assaying of small quantities of test compounds, for example, in 96-well plates, and the reduced concentration of dansylamide advantageously permits the detection of test compounds that have a wide range (≤500 nM) of characteristic dissociation constants. The following materials are used:
100. mM sodium phosphate buffer, pH 7.4
0.6 μM dansylamide (Sigma D-3882)
0.3 μM bovine carbonic anhydrase (Sigma C-3934) inhibitor
Reactions are carried out in 50 μL total volume in 96-well plates, preferably, Dynatech MicroFluor plates, white with 'U' bottom, containing the test compounds. The assay mix is prepared immediately before use, and 50 μL of the assay solution is pipetted into each well of plates in which the test compounds are previously dried. The plates are spun briefly in a tabletop centrifuge before reading fluorescence.
Fluorescence is read in a Perkin-Elmer LS 50B spectrofluorimeter fitted with a Well Plate Reader Accessory using an excitation
wavelength of 274 nm (2.5 nm slit) and an emission wavelength of 454 nm (20 nm slit), with a 390 nm cutoff filter in place. Fluorescence measurements are averaged over 1 sec for each well. To identify wells in which inhibitors are present, first a plate with no exogenous inhibitors is read, which typically gives a fluorescence reading of 2.6- 3.1 (typical standard deviation ± 0.06) for a given assay solution. In plates containing inhibitor candidates, active inhibitors cause a decrease in the fluorescence signal of greater than 5 times the standard deviation.
To distinguish high-affinity from low affinity candidates, 5 μL of a 2 mM stock of dansylamide in DMSO is added to the above test solution, and the assay repeated as above. Typical readings are 7.5 to 8.5±0.4 (standard deviation) among previously identified inhibitors. High-affinity compounds lower the signal by greater than 3 standard deviations). Thus, the increased concentration of dansylamide is sufficient to displace relatively weak inhibitors (e.g., chlorothiazide, Ki - 75 nM) without displacing relatively strong inhibitors (e.g.,
acetazolamide, Ki ~ 7.5 nM).
Bead Lawn Assay (General Method). An enzyme of interest is incorporated into a gellable gum such as silica gel, agar, agarose, pectin, polyacrylamide, gelatin, starch, and gellan gum, preferably a low melting-temperature agarose gel (0.5-2.0%, wt./vol.), which is layered on top of a lawn, no greater than one bead in thickness, of solid supports with attached ligands. The detection of an active combinatorial library member is accomplished by photoeluting the ligands from the beads in situ by exposure to U.V. light. To minimize premature photoelution, the beads are preferably protected from ambient light sources prior to U.V. exposure. The beads are evaluated by placing a second layer, preferably low-melt agarose gel, containing a substrate on top of the one containing the enzyme and the photoreleased library members, and allowing enzymic conversion of substrate into product by diffusion of the substrate into the enzyme-containing gel. The substrate is preferably one that produces a photometric change upon conversion into product; e.g., the generation of a colored product, a fluorescent product, or a chemiluminescent reaction (where one of the products is a photon). The second layer may comprise a gellable gum such as silica gel, agar, agarose, pectin, polyacrylamide, gelatin, starch, and gellan gum, or a solid material such as a matrix containing an array of fluorogenic-pellets. Inhibition of the enzyme by a library member results in a difference in appearance in the vicinity of the attached bead and allows for selection of the bead and the identifiers which encode for the inhibitor. This technique may be used with a variety of enzymes, for example:
Acid Phosphatase Furin
Activated Protein C γ-Glutamyltranspeptidase
Alkaline Phosphatase Granzymes A & B
Aminopeptidases B & M HIV Protease
Amyloid A4-Generating Enzyme IL-1B Convertase
Angiotensinase Kallikrein
Aryl Sulfatase Lysozyme
β-Galactosidase Mast Cell Protease
β-Glucosidase Peroxidase
β-Glucuronidase Plasmin
Calpains I & II Prohormone Convertase
Cathepsins B, C, D, & G rANP Precursor Processing Enzyme Cholinesterase Renin
Chymotrypsin Spleen Fibrinolytic Proteinase
Collagenase Staphylocoagulase
Dipeptidyl Peptidases I- IV Thrombin
Elastase Tissue Plasminogen Activator Endothelin Converting Enzyme Trypsin
Factor Xa Tryptase
Factor XIa Urokinase
Factor Xlla Df-Protease
A bead lawn assay for testing carbonic anhydrase inhibition preferably comprises agarose for both layers, bovine carbonic anhydrase, and fluorescein diacetate.
Bead Lawn Assay (Carbonic Anhydrase). Beads to be tested are arrayed in a minimal amount of methanol in a 60 mm polystyrene tissue culture dish and then all the methanol allowed to evaporate. A 2.5% (wt./vol.) mixture of agarose (SeaPlaque, FMC BioProducts, Rockland, ME) in 20 mM sodium phosphate buffer (pH 7.4) is heated on a hot plate until the agarose dissolves and then is equilibrated to 37°C in a water bath. A separate stock of the same buffer is also equilibrated to 37°C. The enzyme layer is prepared as follows: 100 μL of a bovine carbonic anhydrase stock (0.5 mg/mL or 53 μM based on absorbance at 280 nm, Sigma #C-3934) is added to 2.15 mL of buffer, and 1.25 mL agarose solution is added to the mixture. The agarose/enzyme solution is poured onto the dish containing the beads and the agarose is allowed to solidify at r.t. for 3-5 min. To identify zones of inhibition, the compounds, which are optionally photoeluted by exposure to 4.7-6 mW/cm2 365 nm UV light for 5 sec. to 1 hr., are overlayed with fluorescein diacetate (FLDA, Molecular Probes, Eugene, OR), which is prepared as follows: to 2.25 mL phosphate buffer is added 10 μL FLDA stock (10 mM in DMF at -20°C) and 1.25 mL agarose (final FLDA concentration: 30 μM). The solution is mixed thoroughly then poured over the enzyme layer in the dish. Zones of inhibition appear after 1-2 min. and intensify over 30-45 min. They are dark against a yellow-green background when illuminated by short-wave UV light (λmax = 254 nm).
Bead Lawn Assay (Inositol Monophosphatase). The assay is similar to that for carbonic anhydrase, with the following
substitutions: The buffer used is 20 mM Tris, 1 mM EGTA, pH 7.8. The enzyme layer contains 1 mg/mL recombinant human inositol monophosphatase (purified from E. colϊ) and 10 mM MgCl2. Three alternative substrates are used: methylumbelliferyl phosphate (Sigma, M-8883), a fluorogenic substrate, detected using filters around λex = 388 nm and λem = 420 nm; or CSPD or CDP-Star (chemiluminescent substrates for alkaline phosphatase, Tropix, Bedford MA), detected directly without requiring filters. The preferred substrate is CSPD.
Methods of Synthesis
The compounds of the present invention can be prepared according to the following methods. At each step in the synthesis each solid support upon which a compound is being synthesized is uniquely tagged to define the particular chemical event(s) occurring during that step. The tagging is accomplished using identifiers such as those of Formula IV, which record the sequential events to which the support is exposed during the synthesis, thus providing a reaction history for the compound produced on each support. The identifiers are used in combination with one another to form a binary or higher order encoding scheme permitting a relatively small number of identifiers to encode a relatively large number of reaction products. For example, when used in a binary code, N identifiers can encode up to 2N different compounds and/or conditions. By associating each variable or combination of variables at each step of the synthesis with a
combination of identifiers which uniquely define the chosen variables such as reactant, reagent, reaction conditions, or combinations of these, one can use the identifiers to define the reaction history of each solid support.
In carrying out the syntheses, one begins with at least 103, desirably at least 104, and generally not exceeding 1015 solid supports. Depending on the pre-determined number of R1/R2 choices for the first step, one divides the supports accordingly into as many containers. The appropriate reagents and reaction conditions are applied to each container and the combination of identifiers which encode for each R1/R2 choice is added and attached. Depending on the chemistries involved, the tagging may be done prior to, concomitantly with, or after the reactions which comprise each choice. As a control, sample supports may be picked at any stage and a portion of their tags detached and decoded to verify that the correct tags are bound to the sample supports. As needed, one may wash the beads free of any excess reagents or by-products before proceeding. At the end of each step, the supports are usually combined, mixed, and again divided, this time into as many containers as pre determined for the number of choices for the second step in the synthesis. This procedure of dividing, reacting, tagging, and remixing is repeated until the combinatorial synthesis is completed.
Scheme 1
Functionalized supports such as amino-functionalized or hydroxy-terminating PEG grafted polystyrene beads are divided into a pre-determined number of reaction vessels and are reacted with a cleavable linker/ligand element 3, which has been pre-formed, to generate 4. Unique tagging of the supports in each reaction vessel is achieved with combinations of identifiers encoded in a binary scheme, e.g., as depicted in Table 1-1 for three choices of R1 and R2. The identifiers are attached by adding a solution of the identifiers (in a 1.5% wt./wt. identifier:solid support ratio) to a batch of supports suspended in CH2Cl2 and shaking the mixture for 30 min. A dilute solution of rhodium trifluoroacetate dimer is added and the mixture is immediately shaken 4 hr and washed in CH2Cl2. The procedure is repeated and the mixture shaken for 14 hr and then washed in DMF/DCM.
Scheme 2
The compounds 4 are pooled, mixed, and divided into a pre-determined number of reaction vessels, each of which is treated with one reagent corresponding to ligand element =CR4R5, in the presence of pyrrolidine to produce 5a, 5b, and 5c. Unique tagging of the supports in each reaction vessel is achieved with combinations of additional identifiers encoded in a binary scheme, e.g., as depicted in Table 1-2 for seven choices of R4R5. Scheme 3
The compounds 5c, where R4/R5/X represents the residue of piperidine, pyrrolidine, or aminocyclohexane, are pooled, mixed, and then divided into a pre-determined number of reaction vessels. The supports in each reaction vessel are uniquely tagged with combinations of additional identifiers encoded in a binary scheme, e.g., as depicted in Table 1-3 for 30 choices of R8 and in Table 1-5 for six choices of R14 and four choices of heteroaryl groups. After removal of any N- protecting Boc group in R4R5, each reaction vessel is treated with one reagent corresponding to ligand element R8 in the presence of solvents such as CH2Cl2, DMF, or EtOH and, when required, bases such as triethylamine or 2,6-lutidine to produce 6 having an R8 substituent at C-2 and a ketone at C-4, i.e., when R6R7 together are O. In Scheme 3, R14 is benzyl, -CH2-Ph-4-F, -CH2-Ph-4-OCH3, -CH2-4-Py, n-pentyl, or-CH2-c-propyl; and heteroaryl is , or
Figure imgf000077_0001
Figure imgf000077_0003
Figure imgf000077_0004
Figure imgf000077_0002
.
Scheme 4
A portion of the compounds 5a, 5b, 5c, and 6 may be pooled, mixed, and then divided into a pre-determined number of reaction vessels where they may be uniquely tagged with combinations of additional identifiers encoded in a binary scheme, e.g., as in Table 1-4 for three choices of R6/R7. Each vessel is treated with sodium borohydride to yield 7 as an alcohol at C-4 or is treated with 1,2-dithioethane and a Lewis acid such as BF3•Et2O to yield 8 as a dithiolane at C-4, or is treated with an appropriate non-beta branched primary amine in the presence of NaCNBH3 in MeOH, optionally with acetic acid, to yield secondary amine 9, or is left untreated.
Compounds 5a, 5b, 5c, 5d, 6, 7, 8 , and 9 are then exposed to UV light (-360 nm) in polar solvents such as DMSO, H2O, or a lower alkanol such as MeOH to cleave the compounds of Formula II from the support/linker complex.
Scheme 5
TentaGel resin may be modified with bis-Boc Lysine to increase the available reaction sites for ligand attachment Bis-Boc-lysine in DMF, HOBt, and DIC are shaken at r.t. and then dry TentaGel resin is added. The mixture is shaken at r.t. for 17 hr and then washed alternately with methanol and DCM and then with THF and dried under vacuum. To deprotect the resin, DCM is added, followed by a 30 % TFA solution in DCM (100 mL). The vessel is shaken at room temperature for 15 min. before adding neat TFA.. The vessel is shaken at room temperature for 2.5 hr at which time the resin is washed with DCM, then treated with a solution of 10% triethylamine in DCM, then washed with DCM and DMF.
For purposes of simplicity, the schemes do not show the use of this bis modification.
Scheme 6
Functionalized supports such as amino-functionalized or hydroxy-terminating PEG grafted polystyrene beads are divided into a pre-determined number of reaction vessels and are reacted with a cleavable linker/ligand element 10, which has been pre-formed, to generate 1 1. Unique tagging of the supports in each reaction vessel is achieved with combinations of identifiers encoded in a binary scheme, e.g., as depicted in Table 2-1 for seven choices of -(CH2)1-6R17. The identifiers are attached by adding a solution of the identifiers (in a 7% wt./wt. identifieπsolid support ratio) to each batch of supports suspended in EtOAc and shaking the mixture for 1 hr. A dilute solution of rhodium trifluoroacetate dimer in DCM is added and the mixture is shaken 15 hr and washed with DCM (4X) and EtOAc (2X). The procedure is repeated for each identifier.
To deprotect the encoded resin, it is suspended in DCM and then agitated with a TFA solution in DCM. The resin is then washed with DCM followed by treatment with triethylamine in DCM and then washed with DCM.
Scheme 7
The compounds 12 are pooled, mixed, and divided into a pre-determined number of reaction vessels, each of which is treated with one acetophenone reagent corresponding to ligand element R2, in the presence of DIC, HOBt, and DMF to produce 4'. Unique tagging of the supports in each reaction vessel is achieved with combinations of additional identifiers encoded in a binary scheme analogous to that in
Table 2-1.
Scheme 8
The compounds 4' are mixed, pooled, and divided into a predetermined number of reaction vessels, each of which is treated with and aldehyde or ketone element corresponding to R4/R5 in the presence of pyrrolidine in methanol at 75°C to produce the compounds 5a', 5b', and 5c'. Unique tagging of the supports in each reaction vessel is achieved with combinations of additional identifiers encoded in a binary scheme analogous to that in Table 2-1.
Scheme 9
The compounds 5c', where R4/R5/X represents the residue of t-Boc protected piperidine, t-Boc protected aminocyclohexane, or other amine functionalized molecules are mixed, pooled, and divided into a predetermined number of reaction vessels. The supports in each reaction vessel are uniquely tagged with combinations of additional identifiers encoded in a binary scheme analogous to that in Table 2-1. After removal of any N-protecting group in R4/R5, each vessel is treated with one reagent such as a chloroformate, isocyanate,
thioisocyanate, carboxylic acid, alkyl or aryl sulfonyl halide, aldehyde, or a haloheteroaromatic compound corresponding to ligand element R8 in the presence of solvents such as CH2Cl2, DMF, EtOH, or methanol. When required, bases such as triethylamine, DBU, or 2,6-lutidine and/or other reagents or combinations of reagents such as DIC,
NaCNBH3, HOBt, and acetic acid are added to produce 6 ', having an R8 substituent at C-2 and a ketone at C-4, i.e. when R6R7 together are O.
Scheme 10
A portion of compounds 5a', 5b', 5c', and &. may be pooled, mixed, and then divided into a pre-determined number of reaction vessels where they may be uniquely tagged with combinations of additional identifiers encoded in a binary scheme analogous to that in Table 2-1. Each vessel is treated with 1) sodium borohydride in methanol to yield 7' as an alcohol at C-4; 2) 1 ,2-dithioethane and a Lewis acid such as boron trifluoride etherate to yield 81 as the dithiolane at C-4; 3) an unhindered primary amine along with
NaCNBH3 in acetic acid/methanol solvent at ca. 75°C to yield 9 ' as an amine at C-4; or 4)is left untreated. Scheme 11
The compounds 9 or 9 ' are divided into a predetermined number of reaction vessels. Each vessel is treated with one reagent such as a chloroformate, isocyanate, thioisocyanate, carboxylic acid, alkyl or aryl sulfonyl halide, aldehyde, or a haloheteroaromatic compound corresponding to ligand element R15 in the presence of solvents such as CH2Cl2, DMF, EtOH, or methanol. When required, bases such as triethylamine, DBU, or 2,6-lutidine and/or other reagents or
combinations of reagents such as DIC, NaCNBH3, HOBt, and acetic acid are added to produce the corresponding compound 13 or 13'.
Scheme 12
Functionalized supports such as amino-functionalized or hydroxy-terminating PEG grafted polystyrene beads are placed into a reaction vessel and are reacted with a cleavable linker/ligand element 10, which has been pre-formed, to generate 1 1'. To deprotect the resin, it is suspended in DCM and ther agitated with a TFA solution in DCM. The resin is then washed with DCM followed by treatment with triethylamine in DCM and then washed with DCM to yield 12'.
In an appropriately sized synthesis vessel is placed HOBt (3 equiv.) and the carboxylic acid Q (X = OH) (3 equiv.) in a solvent such as DMF. DIC (3 equiv.) is added and the vessel agitated for 15 min. before adding the amino resin 12' (1 equiv. of amino sites). The resin is agitated for 5 hrs., then washed with alternating DCM and MeOH (5X each) and then with THF (2X) to yield 14.
In an appropriately sized synthesis vessel is placed the amino resin 12' (1 equiv. of amino sites). A solvent such as DCM is added, followed by an organic base such as triethylamine, pyridine, Hiinig's base (di-isopropylethylamine), or 2,6-lutidine (10 equiv.). The resin is agitated for 15 min. before adding the acid halide Q (X = Cl, Br) (5 equiv.) as a dilute solution in a solvent such as DCM. The resin is agitated for 4 hrs. and then washed with DCM and MeOH (5X each) to yield 14.
Figure imgf000081_0001
Figure imgf000082_0001
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000085_0001
Figure imgf000086_0001
Figure imgf000087_0001
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0001
Figure imgf000091_0001
Figure imgf000092_0001
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
The invention is further defined by reference to the following examples, which are intended to be illustrative and not limiting.
PREPARATION 1
IDENTIFIERS
Twelve compounds of the general formula:
Figure imgf000096_0001
wherein:
n = 3-12 and Ar is pentachlorophenyl or
n = 5-6 and Ar is 2,4,6-trichlorophenyl
were prepared according to Scheme 13 and the following illustrative example. a) Methyl vanillate (0.729 g, 4.0 mmol), 1-hydroxy-9-(2,3,4,5,6-pentachlorophenoxy)nonane (1.634 g, 4.0 mmol) and triphenylphosphine (1,258 g, 4.8 mmol) were dissolved in 20 mL dry toluene under argon. DEAD (0.76 mL, 0.836 g, 4.8 mmol) was added dropwise and the mixture was stirred at 25°C for one hr. The solution was concentrated to half volume and purified by flash chromatography eluting with DCM to give 1.0 g (1.7 mmol, 43%) of the product as a white crystalline solid.
b) The methyl ester from Step (a) (1.0 g, 1.7 mmol) was dissolved in 50 mL THF, 2 mL water was added, followed by LiOH (1.2 g, 50 mmol). The mixture was stirred at 25°C for one hr. then refluxed for 5 hr. After cooling to 25°C, the mixture was poured onto ethyl acetate (200 mL) and the solution was washed with 1 M HCl (3× 50 mL) then sat'd aq. NaCl (1× 50 mL) and dried over sodium sulfate. The solvent was removed and the crude acid azeotroped once with toluene. The crude material was dissolved in 100 mL toluene, 10 mL (1.63 g, 14 mmol ) thionyl chloride was added, and the mixture was refluxed for 90 min. The volume of the solution was reduced to approx. 30 mL by distillation, then the remaining toluene was removed by evaporation.
c) The crude acid chloride from Step (b) was dissolved in 20 mL dry DCM and cooled to -70°C under argon and a solution of approx. 10 mmol diazomethane in 50 mL anhydrous ether was added. The mixture was warmed to r.t. and stirred for 90 min. Argon was bubbled through the solution for 10 min., then the solvents were removed by evaporation and the crude material was purified by flash chromatography, eluting with 10-20% ethyl acetate in hexane. The diazoketone (0.85 g, 1.4 mmol, 82% yield over three steps) was obtained as a pale yellow solid.
In alternate Step (c) there is a change to the final diazomethylation step, whereby the ao.d chloride is reacted with (trimethylsilyl)diazomethane and triethylamine to give the identifier, which can then be used without further purification. With this alternate step, the identifier can be obtained in high yield with no chloromethylketone byproduct. Also, purification by flash chromatography is no longer necessary, which in some cases has resulted in significant acid-catalyzed decomposition of the identifier.
Alternate Step c). To a solution of the acid chloride (3.8 mmol, 1.00 equiv.) and 1.85 mL (13.3 mmol, 3.50 equiv.) of
triethylamine in anhydrous THF/acetonitrile (1:1) at 0°C under argon was added 5.7 mL (11.4 mmol, 3.00 equiv.) of a 2.0 M solution of (trimethylsilyl)diazomethane in hexanes. The resulting orange solution was stirred at 0°C for 2 hr, then at 25°C for 17 hr. (If a precipitate formed immediately upon addition of (trimethylsilyl)diazomethane, CH2Cl2 was added until the precipitate redissolved). EtOAc was added (250 mL), and the organic layer washed with saturated aq. NaHCO3 (100 mL) and H2O (100 mL), then dried (anhydrous MgSO4). Removal of the volatiles in vacuo gave the product as yellow crystals in 60-100% yield.
The other 11 identifiers of Formula IV were prepared by analogous synthetic routes, steps (a), (b), and (c). In the synthesis of Example 1, the 12 identifiers were used to encode the combinatorial library. In Step 1, pentachlorophenyl identifiers where n = 11-12 (abbreviated C1 1Cl5 and C12Cl5 were used in the following binary encoding scheme: 01 = (n = 12) and 10 = (n = 11). In Step 2, pentachlorophenyl identifiers where n = 8-10
(abbreviated C8Cl5, C9Cl5 , and C10Cl5) were used and encoded as follows: 001 = (n = 10), 010 = (n = 9), and 100 = (n = 8). In Step 3, pentachlorophenyl identifiers where n = 3-7 (abbreviated C3Cl5,C4Cl5, C5Cl5, C6Cl5, and C7Cl5) were used and encoded as follows: 00001 = (n = 7), 00010 = (n = 6), 00100 = (n = 5), 01000 = (n = 4), and 10000 = (n = 3). In Step 4, trichlorophenyl identifiers where n = 5-6 (abbreviated C5Cl3 and C6Cl3) were used and encoded as follows: 01 = (n = 6) and 10 = (n = 5).
Thus, in Step 1 reagent 3 (Table 1-1) is encoded "11" which represents tagging this choice in the synthesis with the two pentachloro-phenyl identifiers where n = 11 and 12.
Figure imgf000099_0001
PREPARATION 2
t-BUTYL 4-(HYDROXYMETHYL)-3-NITROBENZOATE t-Butyl 4-(acetoxymethyl)-3-nitrobenzoate was prepared as described by Barany and Albericio, J. Am. Chem. Soc. 1985, 107, 4936-4942. The reference's final procedure for hydrazinolysis of the acetate using hydrazine hydrate in CHCl3 at 25°C produces only trace amounts of the desired hydroxymethyl final product, which is the t-butyl ester pre-cursor of the photocleavable linker used herein.
However, hydrazinolysis using hydrazine hydrate in MeOH at 25 °C produces t-butyl 4-(hydroxymethyl)-3-nitrobenzoate in high yield. Using MeOH as solvent, only the desired final product is obtained in near quantitative yield (93%). t-Butyl 4-(hydroxymethyl)-3-nitrobenzoate: To a solution of 14.1 g (47.7 mmol, 1.00 equiv.) of t-butyl 4-(acetoxymethyl)-3-nitrobenzoate in MeOH (200 mL) was added 27.0 mL (477 mmol, 10.0 equiv.) of hydrazine hydrate (55% hydrazine). The resulting yellow solution was stirred at 25 °C for 4 hr. EtOAc (250 mL) and saturated aq. NaCl (85 mL) were added, and the organic layer collected after shaking. The organic layer was washed further with saturated aq. NaCl (2 × 85 mL), and then dried (MgSO4). Removal of volatiles in vacuo gave the product in 93% yield as yellow crystals.
PREPARATION 3
ALLYL 4-(HYDROXYMETHYL)-3-NITROBENZOATE
In a 100 mL round bottom flask was placed 4-hydroxymethyl-3-nitrobenzoic acid (1.97 g, 10 mmol). Allyl alcohol (20 mL) was added, followed by p-toluenesulfonic acid (0.190 g, 1 mmol). The mixture was heated to reflux for 24 hr., at which time all the volatiles were removed in vacuo. The residue was taken up in EtOAc and washed with sat'd KHCO3. The organic layer was dried over MgSO4 and concentrated to afford the title compound as a cream colored solid; 2.4 g (100%). PREPARATION 4
METHYL 4-(HYDROXYMETHYL)-3-NITROBENZOATE
Following the procedure of Preparation 3, but using methanol instead of allyl alcohol, the title compound was prepared in 57% yield.
PREPARATION 5
BIS-LINKER MODIFIED RESIN
Step 1 Addition of bis-Boc lysine
In a 250 mL synthesis vessel was placed bis-Boc-(L)-lysine (7.71g, 22.2 mmol) as a solution in DMF (150 mL). HOBt (2.84g, 21.0 mmol) was added followed by DIC (3.25 mL, 21.0 mmol) and the solution shaken at r.t for 15 min. before adding TentaGel resin (25.8 g, approximately 7.2 mmol amino sites). The mixture was shaken at r.t. for 17 hr and then washed alternately with methanol and DCM (5X each) and then with THF (2X) and dried under vacuum.
Step 2 Deprotection
Into each of seven 250 mL synthesis vessel was placed modified TentaGel resin (8.0 g, approx. 4.5 mmol of N-Boc amine sites). DCM (75 mL) was added followed by a 30 % TFA solution in DCM (100 mL). The vessel was shaken at room temperature for 15 min before adding neat TFA (15 mL). The vessel was shaken at room temperature for 2.5 hr at which time the resin was washed with DCM (2X). The resin was then treated with a solution of 10% triethylamine in DCM (2×150 mL) shaking for 20 min. each time. The resin was then washed with DCM (4X) and DMF (1X).
PREPARATION 6
t-Boc-PROTECTED AMINO ACID
In a 1 L flask was placed 3-nitro-4-(bromomethyl) benb zoic acid (20.03 g, 77.0 mmol). THF (300 mL) was added followed by 4- methoxybenzylamine (10.0 mL, 77.0 mmol) and triethylamine (35 mL). The resulting clear solution was stirred at r.t. for 17.5 hr. Solid di-tert-butyl dicarbonate (16.8 g, 77.0 mmol) was added, followed by DMF (100 mL) and the resulting suspension stirred at r.t. for 72 hr. The reaction mixture was concentrated in vacuo and the residue taken up in ethyl acetate, washed with 1 N HCl (X2), dried (Na2SO4), filtered and concentrated to afford a dark brown oil. Purification via flash chromatography (ethyl acetate±exane) resulted in a yellow foam which was triturated with acetonitrile to give the expected protected amino acid (Table 2-1 , compound 4) as a fine white powder (9.91g, 31 %).
PREPARATION 7
t-Boc-PROTECTED AMINO ACID
Substantially following the procedure of Preparation 6, but substituting the appropriate amine for 4-methoxybenzylamine, the remaining compounds of Table 2-1 are prepared.
EXAMPLE 1
1299 COMPOUND LIBRARY
Step l
a) R1/R2
To a solution of t-butyl 4-hydroxymethyl-3-nitrobenzoate (2 g, 7.89 mmol, 1 equiv.), 2,4-dihydroxyacetophenone (1.20 g, 7.89 mmol, 1 equiv.), and triphenylphosphine (2.69 g, 10.26 mmol, 1.3 equiv.) in toluene (20 mL) was added dropwise DEAD (1.79 g, 10.26 mmol, 1.3 equiv.). After addition was complete the mixture was stirred for 16 hours at room temperature. The solvent was removed in vacuo and the residue was purified by flash chromatography (SiO2, eluted with 10% ethyl acetate in hexanes) affording 1.47 g of the product (48% yield).
The t-butyl ester (500 mg, 1.29 mmol, 1 equiv.) above was dissolved/suspended in DCM (8 mL) and treated with TFA (3 mL). The mixture was stirred at room temperature for 8 hours. The DCM and TFA were removed in vacuo affording a white solid. This was azeotroped once with toluene then dried in vacuo affording 427 mg (100% yield) of the carboxylic acid.
The acid (636 mg, 1.92 mmol, 1.5 equiv.) prepared above was dissolved in DMF (40 mL) and added to divinylbenzene-cross-linked, polyethyleneglycol-grafted polystyrene beads (TentaGel® S NH2, Rapp Polymere) (4.0 g, 0.32 mmol/g, 1.28 mmol, 1 equiv.) in a Merrifield reaction vessel. The resin was suspended by agitation, then HOBt (259 mg, 1.92 mmol, 1.5 equiv.) and DIC (0.31 mL, 1.92 mmol, 1.5 equiv.) were added in that order. The resin was agitated at room temperature for 7 hours at which time it gave a negative Kaiser test. The resin was filtered and washed (DMF 3×50 mL, DCM 3×50 mL) then dried in vacuo.
The two other dihydroxyacetophenones were attached to the resin via the photocleavable linker in an analogous manner using the reagents of Table 1-1.
Alternate a)
In an analogous fashion the allyl and methyl esters were prepared from allyl 4-hydroxymethyl-3-nitrobenzoate (Preparation 3) and methyl 4-hydroxymethyl-3-nitrobenzoate (Preparation 4).
In a 10 mL flask was placed the allyl ester (110 mg. 0.3 mmol). Methylene chloride (2 mL) was added followed by tetrakis-triphenylphospine palladium(0) (11.5 mg, 0.01 mmol) and the mixture cooled to 0°C. Pyrrolidine (50 mL, 0.6 mmol) was added and the reaction stirred at 0°C for 45 min. The mixture was diluted with EtOAc (10 mL) and washed with 3.5N HCl. The organic layer was dried (MgSO4), filtered, and concentrated to afford a yellow solid; 90.6 mg.
In an analogous manner the methyl ester was deprotected by basic hydrolysis using a mixture of dilute NaOH and THF.
b) Encoding of Step 1
Quantities of the three resin batches (2.5 g) from Step 1(a) were placed in separate synthesis vessels and each was suspended in DCM (20 mL). The three appropriate binary coding mixtures (Table 1-1) for each batch of resin were prepared by dissolving the
appropriate choice (37.5 mg) or choices (37.5 mg of each) of C12Cl5 and C11Cl5 -linker diazoketone (Preparation 1) in DCM (1 mL for each solution). These solutions were added to the appropriate synthesis vessel and the resin was agitated for 30 mins.
Rhodium trifluoroacetate dimer (1 mL of a 1 mg/mL solution in DCM) was added to each of the vessels and the resin was agitated at room temperature for 4 hours. Each batch of resin was then filtered and washed with DCM (2×20 mL) then each was resuspended in DCM (20 mL) and treated a second time with the appropriate binary encoding mixture as described above. The resin was again agitated for 30 mins before addition of the rhodium triflouroacetate dimer. The same quantities of catalyst and diazoketone compounds were used in the second coupling step as in the first. The resin was agitated for 14 hours. Each resin batch was then washed with DCM (5×20 mL) then the batches were combined and the entire library (three compounds) was washed with DCM (10×50 mL).
Step 2.
a) Cyclocondensation Reactions
The dried resin from Step 1(b) was divided into four batches of 1.5 g (cα. 0.42 mmol) and three additional batches of 0.2g (cα. 0.056 mmol). The 1.5g batches were placed into 25 mL round-bottomed flasks and the 0.2 g batches were placed into 5 mL round-bottomed flasks. The portions of resin were suspended in methanol (15 mL in the four flasks with 1.5 g of resin, 2 mL in the three flasks with 0.2 g of resin) and pyrrolidine (0.6 mL, 7.2 mmol, cα. 15 equiv. in the flasks with 1.5 g of the resin; 0.08 mL, 0.96 mmol, cα. 15 equiv. in the flasks with 0.2 g of resin) was added to each flask. The reaction vessels were then allowed to stand for 5 min. to allow mixing of the reagents. The appropriate ketone (>10 equiv.) was then added to the vessels. The four BOC protected aminoketones were added to the flasks containing 1.5 g of resin and the other ketones were added to the flasks containing the 0.2 g of resin. The mixtures were heated at 75°C for 16 hr. The flasks were then cooled to room temperature and each batch of resin was poured into a separate sintered funnel and washed thoroughly with DMF (3×20 mL) and DCM (3×20 mL). b) Encoding of Step 2
Each batch of resin from Step 2(a) was placed into a separate synthesis vessel and was suspended in DCM (5 mL for the batches of 1.5 g of resin, 1 mL for the batches containing 0.2 g of resin). The seven appropriate binary coding mixtures (see Table 1-2) for each batch of resin were prepared by dissolving the appropriate choice (22.5 mg if added to a batch of 1.5 g of resin; 3.0 mg if added to a batch of 0.2 g of resin) or choices (22.5 mg of each if added to a batch of 1.5 g of resin; 3.0 mg of each if added to a batch of 0.2 g of resin) of C10Cl5, C9Cl5, and C8Cl5 linker-diazoketone (Preparation 1) in DCM (1 mL for each solution). These solutions were added to the appropriate synthesis vessel and the resin was agitated for 30 mins.
Rhodium trifluoroacetate dimer (1 mL of a 1 mg/mL solution in DCM) was added to each of the vessels and the resin was agitated at room temperature for 4 hr. Each batch of resin was then filtered and washed with DCM (2×20 mL) then each was resuspended in DCM (5 mL for the batches of 1.5 g of resin, 1 mL for the batches of 0.2 g of resin) and treated a second time with the appropriate binary encoding mixture as described above. The resin was again agitated for thirty mins before addition of the rhodium trifluoroacetate dimer. (The same quantities of catalyst and diazoketone compounds were used in the second coupling step as in the first.) The resin was then agitated for 16 hr. Each resin batch was then washed with DCM (5×20 mL). The four batches of 1.5 g of resin were combined and washed with DCM (10×50 mL). These combined batches were then reacted further in Step 3.
The three batches of 0.2 g of resin were combined and washed with DCM (10×20 mL). These combined batches were not used in Step 3 but were saved for Step 4.
Step 3
a) Encoding of Step 3
The four batches of 1.5 g of resin which had been combined in Step 2(b) were now divided into thirty lots of 170 mg each in 1 dram shell vials (Fisher Scientific) and each was suspended in DCM (2 mL). The thirty appropriate binary coding mixtures (see Table 1-3) for each batch of resin were prepared by dissolving the appropriate choice (3 mg) or choices (3 mg of each) of C7Cl5, C6Cl5, C5Cl5, C4Cl5, and C3Cl5 linker-diazoketone (Preparation 1) in DCM (1 mL for each solution). These solutions were added to the appropriate synthesis vessel and the resin was agitated for 30 mins.
Rhodium trifluoroacetate dimer (1 mL of a 1 mg/mL solution in DCM) was added to each of the vessels and the resin was agitated at room temperature for 4 hr. The supernatant solution was then decanted away from the resin with a Pasteur pipette. The resin was washed twice with DCM (3 mL) and the washings removed by Pasteur pipette. Each batch of resin was resuspended in DCM (2 mL) and treated a second time with the appropriate binary encoding mixture as described above. The resin was again agitated for thirty minutes before addition of the rhodium trifluoroacetate dimer. (The same quantities of catalyst and diazoketone compounds were used in the second coupling step as in the first.) The batches of resin were then agitated for 16 hr. Each resin batch was then transferred to a small Merrifield reaction vessel and washed with DCM (3×15 mL), DMF (2×15 mL), and DCM again (2×15 mL). b) Deprotection
Each batch of resin was treated with a 50% solution of TFA in DCM (6 mL:6 mL). The resin was agitated for 2 hr and then filtered and washed with DCM (3×15 mL). The resin was then treated with a 10% solution of triethylamine in DCM (1 mL:9 mL) and agitated for 10 mins. This treatment was repeated once. The resin was filtered and washed with DCM (4×10 mL). c) Addition of R8
To each of the first six flasks was added DCM (5 mL) and the resin was agitated for 10 mins. 2,6-Lutidine (0.11 mL, 20 equiv.) was added to each flask followed by a solution of the appropriate chloroformate (Table 1-3) in DCM (5 mL) and the resin was agitated for 4 hr. Except for isopropylchloroformate (Aldrich), the
chloroformates were prepared from the appropriate alcohols by treating the alcohols (0.1 g) with a solution of phosgene in toluene (5 mL of a 1.8 M solution) for 1 hr, then evaporating to dryness in vacuo ,and then redissolving in DCM (5 mL).
To flasks 8, 9, and 10 was added ethanol (10 mL) and the appropriate isocyanate (Table 1-3) (0.1 mL, cα. 10 equiv.) and the resin was agitated for 4 hr.
To flasks 1 1 , 12, and 13 was added ethanol (10 mL) and the appropriate isothiocyanate (0.1 mL, 0.1 g of the naphthalene-isothiocyanate, cα. 10 equiv.) and the resin was agitated for 4 hr. To flasks 7 and 14-22 was added DMF (10 mL) and the appropriate carboxylic acid (cα. 10 equiv.) and HOBt (0.103 g, cα. 15 equiv.). The flasks were agitated for 30 mins then DIC (0.12 mL, cα. 15 equiv.) was added to each flask and the resin was agitated for 4 hr.
To flasks 23-30 was added DCM (10 mL) and triethylamine (0.15 mL, cα. 15 equiv.) and the resin was agitated for 15 mins. The appropriate sulfonyl chloride (cα. 10 equiv.) was added to the reaction vessels and the resin agitated for 4 hr.
The flasks were filtered and the resin washed with DCM (3×10 mL). All of the resin was combined in one large synthesis vessel and was washed with DCM (3×50 mL), DMF (3×50 mL), and DCM again (3×50 mL). The resin was dried in vacuo.
Alternative Step 3
a) Encoding of Alternative Step 3
The remaining 900 mg of resin from the four combined batches of 1.5 g from Step 2(b) which had not been used in Step 3 was divided into ten portions of 90 mg, and each portion placed in a separate 1 dram shell vial (Fisher Scientific). The ten appropriate binary coding mixtures (see Table 1-5) for each batch of resin were prepared by dissolving the appropriate choice (1.5 mg) or choices (1.5 mg each) of C7Cl5, C5Cl5, C4Cl5, and C3Cl5 linker-diazoketone (Preparation 1) in DCM (1 mL for each solution). These solutions were added to the appropriate synthesis vessels and the resin was agitated for 30 min.
Rhodium trifluoroacetate dimer (1 mL of a 1 mg/mL solution in DCM) was added to each of the vessels and the resin was agitated at room temperature for 4 hr. The supernatant solution was then decanted from the resin. The resin was washed (DCM 2× 3 mL) and the washings removed by Pasteur pipette. The resin was then treated a second time with solutions of the appropriate binary coding mixtures and agitated for 30 min. before the addition of the rhodium trifluoroacetate dimer. The same quantities of catalyst and diazoketone compounds were used in the second coupling as in the first. The batches of resin were then agitated for 16 hr. The resin was then transferred into small Merrifield synthesis vessels and washed (DCM 6× 15 mL). b) Deprotection.
Each batch of resin was treated with a solution of TFA in DCM (4 mL:4 mL). The resin was agitated for 1 hr, then filtered and washed with DCM (2× 15 mL). The resin was then treated with a solution of piperidine in DCM (4 mL:4 mL) and agitated for 15 min. This treatment was repeated once. Each batch of beads was washed with methanol (2× 15 mL) ana DCM (4× 15 mL). Flasks 1-4 were washed with THF (3× 15 mL).
c) Heteroarylation Reactions
The resin in flasks 1-4 was suspended in THF (6 mL).
Flasks 1-3 were then treated wiάi DBU (190 μL, cα. 40 equiv.) followed by the appropriate heteroaryl chloride (cα. 20 equiv.). Flasks 1 and 2 were heated at 55 °C for 16 hr. Flask 3 was heated at reflux for 16 hr. Flask 4 was treated with triethylamine (700 μL) and the appropriate heteroaryl chloride (cα. 20 equiv.). The resin was shaken at r.t. for 16 hr. Each batch of resin was then washed in THF (2× 15 mL) and dried in vacuo.
d) Reductive Alkylations
The resin in flasks 5-10 was suspended in DMF (8 mL) and the appropriate aldehyde (cα. 67 equiv.) added. Acetic acid (160 μL) was added to each of the flasks followed by sodium cyanoborohydride (cα. 67 equiv.). Flasks 5, 6, 7, 9, and 10 were shaken at r.t. for 16 hr. Flask 8 was heated to 55 °C for 16 hr. Each batch of resin was filtered and washed with DMF (3× 15 mL). Each of the reductive alkylation reactions was repeated under the same conditions. The batches of resin were washed with DMF (2× 15 mL), methanol (3× 15 mL), and DCM (3× 15 mL). The resin was then mixed, washed with DCM (2× 20 mL), and dried in vacuo.
This part of the library did not undergo further elaboration.
Step 4
a) Encoding of Step 4
To the combined resin from Step 3(c) was added 45 mg of resin from each of the seven flasks from Step 2(b) and the resin was washed and mixed thoroughly with DCM (3×50 mL). From this mixture was weighed out three portions of 800 mg of resin and these were placed into three separate Merrifield synthesis vessels and suspended in DCM (10 mL). The three appropriate binary coding mixtures (see Table 1-4) for each batch of resin were prepared by dissolving the appropriate choice (24 mg) or choices (24 mg of each) of the C6Cl3 and C5Cl3 linker-diazoketone compound in DCM (1 mL for each solution). These solutions were added to the appropriate synthesis vessel and the resin was agitated for 30 mins.
Rhodium trifluoroacetate dimer (1 mL of a 1 mg/mL solution in DCM) was added to each of the vessels and the resin was agitated at room temperature for 4 hr. Each batch of resin was then filtered and washed with DCM (2×20 mL) then each was resuspended in DCM (10 mL) and treated a second time with the appropriate binary encoding mixture as described above. The resin was again agitated for 30 mins before addition of the rhodium trifluoroacetate dimer. The same quantities of catalyst and diazoketone compounds were used in the second coupling step as in the first. The resin was agitated for 14 hr.
Each resin batch was then washed with DCM (3×20 mL) and then filtered.
b) Carbonyl Reaction (addition of R6 and R7)
The resin in flask 1 was resuspended in DCM (6 mL) and
1 ,2-ethanedithiol (1 mL) and boron trifluoride etherate (1 mL) were added. The flask was shaken at room temperature for 6 hr. The resin was then washed with DCM (20 mL) and then resuspended in DCM (6 mL) and treated once more with ethanedithiol (1 mL) and boron trifluoride etherate (1 mL). The resin was agitated at room
temperature for 14 hr. The resin was then filtered and washed with DCM (5×20 mL).
The resin in flask 2 was suspended in methanol (5 mL) and solid sodium borohydride (200 mg) was added cautiously. The flask was vented and allowed to shake gently for 1 hr. The resin was filtered and resuspended in methanol and the reduction process repeated a total of 5 times at 1 hr intervals using 200 mg of sodium borohydride each time. After the final cycle the resin was washed with methanol (3×20 mL) and DCM (3×20 mL).
The resin in flask 3 was not reacted further. The resin from the three flasks was combined and washed with DCM (5×50 mL) and then dried in vacuo. A portion (500 mg) of the resin was suspended in DCM (5 mL) and TFA (5 mL) and shaken for 2 hr. The resin was then treated twice with a 10% solution of triethylamine in DCM (10 mL) and washed with DCM (5×20 mL). The resin was then dried in vacuo. d) Decoding Procedure
A bead was placed in a 1.3 mm diameter pyrex capillary with 2 μL of acetonitrile. Ceric ammonium nitrate solution (2 μL of a 0.1 M aq.. solution) and hexane (3 μL) were added and the two-phase mixture centrifuged briefly. The tube was sealed and left at 35 °C for 16 hrs, then opened. The organic layer was removed by syringe and mixed with 1 μL of N,O-bis(trimethylsilyl)acetamide. The silated tag solution (1 μL) was analyzed by GC with electron capture (EC) detection.
The GC analysis was performed with a Hewlett Packard 5890 plus gas chromatograph. On column injection into a 5 m, 0.32 mm retention gap connected to a 25 m, 0.2 mm crosslinked 5% phenylmethyl silicone column was used. The temperature program was set at 200 °C for 1 min and then increased at a rate of 15°C/min from 200-320 °C. The pressure program was set at 20 psi for 1 min, then increased at 2 psi/min to 40 psi with a total run time of 10 min. The EC detector was maintained at 400 °C and the auxiliary gas was set at 35 psi.
Figure imgf000111_0002
Figure imgf000112_0001
Figure imgf000113_0001
Figure imgf000113_0003
EXAMPLE 2
87.906 COMPOUND LIBRARY
Step 1
a) Addition of (CH2) 1-6R17
In a 250 mL synthesis vessel was placed the deprotected modified TentaGel resin (8.0 g, approx. 4.5 mmol of amine sites) from Preparation 5. HOBt (1.81g, 13.4 mmol) was added followed by the N-Boc-p-methoxybenzylamino acid (Table 2-1, compound 4) (5.60g, 13.4 mmol) and DMF (150 mL). The mixture was shaken at r.t. for 10 min. before adding DIC (2.1 mL, 13.4 mmol). The mixture was shaken at r.t. for 16 hr and then washed alternately with methanol and DCM (4X each) and then with EtOAc (2X). Analysis of the resin via the standard Kaiser ninhydrin test indicated that the coupling reaction was complete.
In six separate vessels, analogous couplings were carried out with the six other Boc-protected amino acids listed in Table 2-1. All coupling reactions were repeated until satisfactory Kaiser ninhydrin test results were obtained (in all cases either one or two couplings). b) Encoding of Step 1 While still in their separate 250 mL synthesis vessels, resin batches number 4, 5, 6, and 7 from Step 1 were suspended in EtOAc (100 mL). Into each of these four vessels was placed the Cl5C7-linker diazoketone (0.56 g) and the mixtures agitated for 1 hr. To each of the four vessels was then added rhodium trifluoroacetate dimer (6 mL of a 1 mg/mL solution in DCM) and the resin was agitated for 15 hr. The resin was then washed with DCM (4X) and EtOAc (2X).
In turn, the Cl5C8-linker diazoketone was applied to resin batches numbered 2, 3, 6, and 7 and the Cl5C 1 1-linker diazoketone was applied to resin batches 1 , 3, 5, and 7. Application of each tagging molecule was done separately and in analogous fashion to that of the Cl5C7-linker diazoketone outlined above. The seven batches of encoded resin were all combined in a 2 L Erlenmeyer flask along with THF (1 L) and mixed thoroughly by swirling and stirring gently with a glass rod. The resin was then recovered by filtration and vacuum dried. Step 2: Addition of R2
a) Deprotection
In a 250 mL synthesis vessel is placed mixed, encoded resin from Step 1 (9 g) along with DCM (just enough to suspend resin). TFA (75 mL of a 30 % solution in DCM) is added and the resin agitated for 3.5 hr. The resin is then washed with DCM (2X) followed by treatment with 10% triethylamine in DCM (2X 20 min. each) and then washed with DCM (4X).
b) Coupling
The deprotected resin from Step 2(a) (9 g) is suspended in
DMF (7 mL). HOBt (2.04 g, 15 mmol) is added followed by the acetophenone acid (Table 2-2, compound 31 (3.36g, 15 mmol) and the mixture agitated for 15 min. DIC (2.3 mL, 15 mmol) is added and the mixture agitated for 21 hr. The resin is washed alternately with DCM and methanol (5X each) and then with EtOAc (4X).
In five separate vessels, analogous couplings are carried out with the five other acetophenone acids listed in Table 2-2.
c) Encoding of Step 2
The six batches of resin from Step 2 are binarily encoded in a fashion analogous to that described above for encoding of Step 1
The six batches of encoded resin are combined in a 2 L Erlenmeyer flask along with THF (1 L) and mixed thoroughly by swirling and stirring gently with a glass rod. The resin is then recovered by filtration and vacuum dried.
Step 3 Addition of R4R5
a) Cyclocondensation reactions
The mixed resin from Step 2 is divided into three batches of 14.4 g (cα. 8.1 mmol) and seven additional batches of 1.5 g (cα. 0.84 mmol). The 14.4 g batches are placed into 250 mL round bottom flasks and the 1.5 g batches are placed in 25 mL round bottom flasks. The portions of resin are suspended in methanol (150 mL in the three flasks with 14.4 g resin, 15 mL in the seven flasks with 1.5 g resin) and pyrrolidine (10.1 mL, 121 mmol, cα. 15 equiv. in the flasks with 14.4 g resin; 1.0 mL, 12.6 mmol, cα. 15 equiv. in the flasks with 1.5 g resin) is added to each flask. The reaction vessels are then allowed to stand for 15 min. to allow mixing of the reagents. The appropriate ketone (5 to 10 equiv.) is then added to the vessels. The three Boc-protected aminoketones from Table 2-3 are added to the flasks containing 14.4 g of resin and the seven other ketones, from Table 2-4, are added to the flasks containing 1.5 g of resin. The mixtures are heated at 75°C for 16 hr. The flasks are then cooled to r.t. and each batch of resin is poured into a separate synthesis vessel of appropriate size and washed
thoroughly with DCM, DMF, and methanol (alternating: 5X each). b) Encoding of Step 3
Each of the ten batches of resin from Step 3(a) is binarily encoded in a fashion analogous to that described for encoding Step 1. c) Mixing and dividing
The seven 1.5 g batches of encoded resin are combined in a
500 mL Erlenmeyer flask along with THF (250 mL) and mixed thoroughly by swirling and stirring gently with a glass rod. The resin is then recovered by filtration and vacuum dried. This combined resin is kept separate from the three 14.4 g batches of resin and is not subjected to the reaction conditions of Step 4, but rather re-divided into three 0.2 g portions and seven 1.4 g portions and saved to be used in Step 5 and alternate Step 5. The three 14.4 g batches of encoded resin are combined in a 2 L Erlenmeyer flask along with THF (1 L) and mixed thoroughly by swirling and stirring gently with a glass rod. The resin is then recovered by filtration, vacuum dried, and used in Step 4.
Step 4
a) Deprotection
Into each of seven 250 mL synthesis vessels is placed mixed, encoded resin from the three combined 14.4 g batches from Step 3 (6 g) along with DCM (just enough to suspend the resin). TFA (75 mL of a 30 % solution in DCM) is added and the resin agitated for 3.5 hr. The resin is then washed with DCM (2X) followed by treatment with 10% triethylamine in DCM (2X 20 min. each) and then washed with DCM (4X). b) Nitrogen elaboration
In the first of the seven 250 mL synthesis vessels containing deprotected resin from Step 4(a) (6 g, cα. 3.4 mmol) is placed DCM (150 mL) and triethylamine (15 equiv.). Phenylsulfonyl chloride (cα. 10 equiv.) is added and the resin agitated for 4 hr. The resin is washed with alternating DCM and methanol (5X each) and then with EtOAc (2
X).
In the second of the seven 250 mL synthesis vessels containing deprotected resin from Step 4(a) (6 g, cα. 3.4 mmol) is placed DCM (150 mL) and triethylamine (15 equiv.). Butryl chloride (cα. 10 equiv.) is added and the resin agitated for 4 hr. The resin is washed with alternating DCM and methanol (5X each) and then with EtOAc (2X).
In the third of the seven 250 mL synthesis vessels containing deprotected resin from Step 4(a) (6 g, cα. 3.4 mmol) is placed DMF (150 mL) and HOBt (cα. 15 equiv.). 4-Carboxy-benzenesulfonamide (cα. 10 equiv.) is added and the resin agitated for 30 min. DIC (cα. 10 equiv.) is added and the resin agitated for 4 hr. The resin is washed with alternating DCM and methanol (5X each) and then with EtOAc (2X).
In the fourth of the seven 250 mL synthesis vessels containing deprotected resin from Step 4(a) (6 g, cα. 3.4 mmol) is placed DMF (150 mL) and acetic acid (3 mL). Benzaldehyde (cα. 50 equiv.) is added and the resin agitated for 30 min. Sodium
cyanoborohydnde (cα. 50 equiv.) is added and the resin agitated for 16 hr. The resin is washed with alternating DCM and methanol (5X each) and then with EtOAc (2X).
In the fifth of the seven 250 mL synthesis vessels containing deprotected resin from Step 4(a) (6 g, cα. 3.4 mmol) is placed DMF (150 mL) and acetic acid (3 mL). Butyraldehyde (cα. 50 equiv.) is added and the resin agitated for 30 min. Sodium
cyanoborohydride (cα. 50 equiv.) is added and the resin agitated for 16 hr. The resin is washed with alternating DCM and methanol (5X each) and then with EtOAc (2X).
The resin from the sixth of the seven 250 mL synthesis vessels containing deprotected resin from Step 4(a) (6 g, cα. 3.4 mmol) is transferred to a 250 mL round bottom flask. THF (150 mL) is added followed by DBU (cα. 40 equiv.). 2-Chloropyrimidine (cα. 20 equiv.) is added. The mixture is heated to 55°C for 16 hr. The resin is transferred back to a 250 mL synthesis vessel, washed with alternating DCM and methanol (5X each), and then with EtOAc (2X).
In the seventh of the seven 250 mL synthesis vessels containing deprotected resin from Step 4(a) (6 g, cα. 3.4 mmol) is placed absolute ethanol (150 mL). Methyl isocyanate (cα. 15 equiv.) is added and the resin agitated for 12 hr. The resin is washed with alternating DCM and methanol (5X each) and then with EtOAc (2X). c) Encoding of Step 4
Each of the seven batches of resin from Step 4(b) are binariiy encoded in a fashion analogous to that described for the encoding of Step 1.
The seven batches of encoded resin are combined in a 2 L
Erlenmeyer flask along with THF (1 L) and mixed thoroughly by swirling and stirring gently with a glass rod. The resin is then recovered by filtration and vacuum dried. This resin is then divided into three batches of 0.7 g each and seven batches of 5.7 g each. The seven 5.7 g. batches are subjected to Step 5. The three 0.7 g batches are subjected to alternate Step 5.
Step 5
a) Encoding
Each of the seven 5.7 g. batches of resin from Step 4(c) and the seven 1.4 g batches from Step 3(b) are binariiy encoded in a fashion analogous to that described for the encoding of Step 1. b) Reductive amination
The seven encoded 5.7 g. batches of resin from Step 5(a) are placed in 200 mL round bottom flasks. The seven encoded 1.4 g. batches from Step 3(c) are placed in 50 mL round bottom flasks. To each of the fourteen flasks is added a solution of 10% glacial acetic acid in methanol (60 mL in the 200 mL flasks, 15 mL in the 50 mL flasks). The appropriate amine from Table 2-6 (cα. 40 equiv.) is added followed by sodium cyanoborohydride (cα. 40 equiv.). Condensers are attached and the mixtures are heated to 75°C for 48 hr. The resin is washed with alternating DCM and methanol (5X each) and then with EtOAc (2X).
Alternate Step 5 a) Thioketalization
One of the three 0.7 g. batches of resin from Step 4(c) and one of the 0.2 g batches of resin from Step 3(c) are placed in two separate 30 mL synthesis vessels. To each is added DCM (6 mL), followed by 1,2-ethanedithiol (1 mL) and boron trifluoride etherate (1 mL). The resin is agitated at r.t. for 6 hr. The resin is washed with DCM (1X) and then treated once more with ethanedithiol (1 mL) and boron trifluoride etherate (1 mL). The resin is agitated at r. t. for 14 hr. The resin is then filtered and washed with alternating DCM and methanol (5X each) and then with EtOAc (2X). b) Reduction
One of the three 0.7 g. batches of resin from Step 4(c) and one of the 0.2 g batches of resin from Step 3(c) are placed in two separate 30 mL synthesis vessels. To each is added methanol (6 mL) and (cautiously) solid sodium borohydride (200 mg). The flasks are vented and allowed to gently shake for 1 hr. The resin is filtered and resuspended in methanol (6 mL) and the reduction process repeated a total of 5 times at 1 hr. intervals using 200 mg portions of sodium borohydride each time. After the final cycle, the resin is washed with alternating DCM and methanol (5X each) and then with EtOAc (2X). c)
One of the three 0.7 g. batches of resin from Step 4(c) and one of the 0.2 g batches of resin from Step 3(c) is left unaltered.
Step 6 a) Mixing
The seven 5.7 g batches of encoded resin from Step 5(b) are combined in a 2 L Erlenmeyer flask along with THF (1 L). The seven 1.4 g batches of encoded resin from Step 5(b) are combined in a 500 mL Erlenmeyer flask. Each batch of resin is mixed thoroughly by swirling and stirring gently with a glass rod. The resin from each flask is recovered by filtration, vacuum dried, and kept separate. b) Nitrogen elaboration.
The mixed and dried resin from the combined 5.7 g.
batches in Step 6(a) (total of cα. 32.5 g.) is divided into ten 3.2 g.
batches and placed in 100 mL synthesis vessels. The mixed and dried resin from the combined 1.4 g. batches in Step 6(a) (total of cα. 9.8 g.) is divided into ten 0.98 g. batches and placed in 30 mL synthesis vessels. These vessels are paired up into ten sets of two where each set has one 100 mL vessel and one 30 mL vessel. Both members of each set are subjected to the same reaction conditions as outlined below.
In the first set of vessels is placed N,N'-bis Boc-(L)-lysine (cα. 10 equiv.) as a solution in DMF (60 mL in the larger vessel, 15 mL in the smaller). HOBt (cα. 15 equiv.) is added and the resin agitated for 15 min. DIC (cα. 10 equiv.) is added and the resin agitated for 4 hr. The resin is washed with DCM (2X) and then treated with TFA (30% solution in DCM) (1.5 hrs.). The resin is then washed with DCM (2X) and treated with 10% triethylamine in DMF (2X, 30 min. each). The resin is washed with alternating DCM and methanol (5X each) and then with EtOAc (2X).
In the second set of vessels is placed N-α-Fmoc-N-ω-Pmc-(L)-arginine (cα. 10 equiv.) as a solution in DMF (60 mL in the larger vessel, 15 mL in the smaller). HOBt (cα.. 15 equiv.) is added and the resin agitated for 15 min.. DIC (cα. 10 equiv.) is added and the resin agitated for 4 hr. The resin is washed with DCM (2X) and then treated with TFA (50% solution in DCM) (1.5 hrs.). The resin is then washed with DCM (2X) and treated with 50% piperidine in DMF (2X, 30 min. each). The resin is washed with alternating DCM and methanol (5X each) and then with EtOAc (2X).
In the third set of vessels is placed DCM (60 mL in the larger vessel, 15 mL in the smaller). N,N-di-n-propyl-N'-cyano-ethylthioformamidine (cα. 15 equiv.) is added, followed by
triethylamine (cα. 20 equiv.) and the resin agitated for 12 hrs. The resin is washed with alternating DCM and MeOH (5X each) and then with EtOAc (2X). In the fourth set of vessels is placed absolute ethanol (60 mL in the larger vessel, 15 mL in the smaller). Methyl isocyanate (cα. 15 equiv.) is added and the resin agitated for 12 hr. The resin is washed with alternating DCM and methanol (5X each) and then with EtOAc (2X).
In the fifth set of vessels is placed absolute ethanol (60 mL in the larger vessel, 15 mL in the smaller). Methyl isothiocyanate (cα.. 15 equiv.) is added and the resin agitated for 12 hr. The resin is washed with alternating DCM and methanol (5X each) and then with EtOAc (2X).
In the sixth set of vessels is placed absolute ethanol (60 mL in the larger vessel, 15 mL in the smaller). Phenyl isocyanate (cα.. 15 equiv.) is added and the resin agitated for 12 hr. The resin is washed with alternating DCM and methanol (5X each) and then with EtOAc (2X).
In the seventh set of vessels is placed absolute ethanol (60 mL in the larger vessel, 15 mL in the smaller). Phenyl isothiocyanate (cα.. 15 equiv.) is added and the resin agitated for 12 hr. The resin is washed with alternating DCM and methanol (5X each) and then with EtOAc (2X).
In the eighth set of vessels is placed DCM (60 mL in the larger vessel, 15 mL in the smaller) and 2,6-lutidine (cα.. 20 equiv.). Isopropyl chloroformate (cα . 15 equiv.) is added and the resin agitated for 4 hr. The resin is washed with alternating DCM and methanol (5X each) and then with EtOAc (2X).
In the ninth set of vessels is placed DCM (60 mL in the larger vessel, 15 mL in the smaller) and triethylamine (15 equiv.). Isobutryl chloride (cα.. 10 equiv.) is added and the resin agitated for 4 hr. The resin is washed with alternating DCM and methanol (5X each) and then with EtOAc (2X).
In the tenth set of vessels is placed DCM (60 mL in the larger vessel, 15 mL in the smaller) and triethylamine (15 equiv.). Methanesulfonyl chloride (cα.. 10 equiv.) is added and the resin agitated for 4 hr. The resin is washed with alternating DCM and methanol (5X each) and then with EtOAc (2X).
Figure imgf000122_0001
Figure imgf000123_0001
Figure imgf000123_0002
Figure imgf000124_0001
Figure imgf000124_0002
Figure imgf000125_0001
Figure imgf000125_0002
Figure imgf000126_0001

Claims

WHAT IS CLAIMED IS:
1. A compound of the formula:
(T'-L)q-ⓢ -C(O)-L'-II' I
wherein: ⓢ is a solid support;
T'-L- is an identifier residue;
-L'-II' is a ligand/linker residue; and
q is 3-30.
2. A compound of Claim 1 wherein: T'-L- is of the Formula:
Figure imgf000127_0001
wherein n = 3-12 when Ar is pentachlorophenyl and n = 3-6 when Ar is 2,4,6-trichlorophenyl; q is 4-12; and
-L'- is
or
Figure imgf000127_0002
Figure imgf000127_0003
wherein the left-hand bond as shown is the point of attachment to the solid support and the right hand bond is the point of attachment to the ligand, and B is O or N(CH2) 1-6R17, with the proviso that in (b) when B is N(CH2) 1-6R17, the ligand is attached to B through a carbonyl group.
3. A compound of Claim 1 wherein -C(O)-L'-II' is:
Figure imgf000128_0001
Figure imgf000128_0002
or
Figure imgf000128_0003
4. A compound of the formula:
Figure imgf000128_0004
wherein
R1 is OH, O(CH2) 1-2OH, OCH2CO2H, CO2H,
O-Z-C(O)NH(CH2) 1-6R17, or
OCH2-4-Phe-C(O)NH(CH2)1-6R17;
R2 is H or lower alkyl;
R3 is H, alkyl, aryl, or arylalkyl;
R4 and R5 is each independently H, lower alkyl, or substituted lower alkyl where the substituents are 1-3 alkoxy, aryl, substituted aryl, carboalkoxy, carboxamido, or
diloweralkylamido; or R4 and R5 taken together are -(CH2)n-, -(CH2)2-O-(CH2)2-, -CH2-O-(CH2)3-, -(CH2)2-NR8-(CH2)2-, -CH2-NR8-(CH2)m-,
-(CH2)2CH(NHR8)(CH2)2-, -(CH2)2-S(O)0-2-(CH2)2- , or
;
Figure imgf000129_0001
one of R6 and R7 is H and the other is H, OH, or N(CH2) 1-6R14R15; or
R6 and R7 taken together are
Figure imgf000129_0002
, , , ,
Figure imgf000129_0003
Figure imgf000129_0004
Figure imgf000129_0007
;
, or
Figure imgf000129_0006
Figure imgf000129_0005
R8 is H, COOR9, CONHR10, CSNHR 1 1, COR12, SO2R13, lower alkyl, aryl lower alkyl, heteroaryl, or heteroaryl lower alkyl, wherein aryl is optionally substituted with 1-3 substituents selected from lower alkyl, lower alkoxy, halo, CN, NH2, COOH, CONH2, carboalkoxy, and mono- or di- lower alkylamino and wherein heteroaryl is a mono- or bicyclic heteroaromatic ring system of 5 to 10 members including 1 to 3 heteroatoms selected from O, N, and S and 0-3 substituents selected from halo, amino, cyano, lower alkyl, carboalkoxy, CONH2, and S-lower alkyl;
R9 is lower alkyl, aryl, aryl lower alkyl, heteroaryl, aryl
substituted by 1-3 substituents selected from alkyl, alkenyl, alkoxy, methylene dioxy, and halo, or a 5 to 6-membered heterocyclic ring wherein the hetero atom is O or N, wherein heteroaryl is a heteroaromatic ring of 5 to 6 members including 1 to 2 heteroatoms selected from O, N, and S and 0-2 substituents selected from lower alkyl, dialkylamino, lower alkoxy, and halo; R10 and R1 1 is each independently lower alkyl, aryl, aryl lower alkyl, or aryl substituted by 1-3 substituents selected from lower alkyl, halo, alkoxy, and haloalkyl;
R12 is lower alkyl, aryl, heteroaryl, aryl lower alkyl,
heteroaryl lower alkyl, a 5- or 6-membered heterocyclic ring containing 1-2 heteroatoms selected from O, S, and N, a 5- or 6-membered heterocyclic ring containing 1-2 heteroatoms selected from O, S, and N lower alkyl, or aryl substituted with 1-3 substituents selected from lower alkyl, alkoxy, halo, sulfamoyl, lower alkyl sulfamoyl, cyano, and phenyl;
R13 is lower alkyl, aryl, or aryl substituted with 1-3 substituents selected from lower alkyl, alkoxy, halo, CN, and haloalkyl; R14 is H; alkyl substituted by 1-3 alkoxy, S-loweralkyl,
sulfamoyl, halo, alkylsulphonamido, or arylsulphonamido; alkenyl; alkynyl; aryl; substituted aryl; heteroaryl;
substituted heteroaryl; heterocycloalkyl;
-CH2NR16C(O)R16; -C(O)NR16R16; -CH2OC(O)R16; or
-CH2SC(O)R16;
R15 is H, alkyl, -C(O)X, -C(S)X, or -C(NCN)NR3R3;
R16 is lower alkyl, substituted lower alkyl, aryl, or substituted aryl;
R17 is H; alkyl substituted by 1-3 alkoxy, S-loweralkyl,
sulfamoyl, halo, alkylsulphonamido, or arylsulphonamido; alkenyl; alkynyl; aryl; substituted aryl; heteroaryl;
substituted heteroaryl; heterocycloalkyl;
-CH2NR16C(O)R16; -C(O)NR16R16; -CH2OC(O)R16; or
-CH2SC(O)R16;
X is alkyl, aryl, arylalkyl, O-loweralkyl, or NR3R3
Z is -(CH2) 1-6-, optionally substituted with 1-3 lower alkyl;
CHR2; Phe-CH2-, where Phe is optionally mono- substituted with halogen, lower alkyl, or alkoxy; or heteroarylene-(CH2)-;
m is 2 or 3;
n is 4-9;
or a pharmaceutically acceptable salt thereof.
5. A compound of Claim 3 wherein R12 is
sulfamoylphenyl.
6. A compound of Claim 3 wherein R12 is
p-sulfamoylphenyl. 7. A compound of Claim 4 wherein:
R1 is OH, OCH2C(O)NH(CH2) 1-6R14, or OCH2-4-Phe- C(O)NH(CH2) 1-6R14;
R2 is H or lower alkyl;
R4 and R5 is each lower alkyl; or R4 and R5 taken together are
-(CH2)5-, -(CH2)2-O-(CH2)2-, -(CH2)2-NR8-(CH2)2-,
-(CH2)2-CH(NHR8)(CH2)2-, -(CH2)2-S-(CH2)2- , or
;
Figure imgf000131_0001
R6/R7 are H/OH, =O, or -S(CH2)2S-;
R8 is H, COOR9, CONHRiO, CSNHR1 1, COR12, SO2R13, .
lower alkyl, aryl lower alkyl, heteroaryl wherein the ring members include 1 to 3 N atoms and the substituents are halo or amino, heteroaryl lower alkyl wherein heteroaryl is 6-membered and the heteroatoms are N, or aryl lower alkyl substituted with 1 substituent selected from lower alkyl, alkoxy, and halo;
R9 is lower alkyl, aryl lower alkyl, aryl, tetrahydrofuranyl, tetrahydropyranyl, or aryl substituted by 1 to 2 substituents selected from lower alkyl, alkenyl, alkoxy, methylene dioxy, and halo;
R10 and R11 is each independently aryl, aryl lower alkyl, or aryl
substituted by 1 substituent selected from lower alkyl, halo, alkoxy, trifluoromethyl, and pentafluoroethyl; R12 is lower alkyl, aryl, aryl lower alkyl, heteroaryl lower alkyl wherein the heteroatoms are N, a 5- or 6-membered heterocyclic ring containing 1-2 heteroatoms selected from
S and N lower alkyl, or aryl substituted with 1 substituent selected from lower alkyl, alkoxy, halo, sulfamoyl, cyano, or phenyl; R13 is lower alkyl, aryl, or aryl substituted with 1 substituent selected from lower alkyl, alkoxy, and halo; or a pharmaceutically acceptable salt thereof.
8. A compound of Claim 4 of the formula:
Figure imgf000132_0001
wherein:
R1 is 6- or 7-OH;
R2 is H or lower alkyl;
R4 and R5 is each methyl; or R4 and R5 taken together are -(CH2)5-,
-(CH2)2-O-(CH2)2-, -(CH2)2-NR8-(CH2)2-,
-CH2-NR8-(CH2)3-, -CH2-NR8-(CH2)2-, or -(CH2)2- CH(NHR8)(CH2)2-;
one of R6 and R7 is H and the other is OH or R6 and R7 taken together are =O or -S(CH2)2S-;
R8 is H, COOR9, CONHR10, CSNHR11, COR12, SO2R13, benzyl, -CH2-Ph-4-F, -CH2-Ph-4-OCH3, -CH2-4-Py, n-butyl, -CH2-c-ρroρyl, , or
Figure imgf000132_0002
Figure imgf000132_0004
Figure imgf000132_0005
Figure imgf000132_0003
; R9 is i-propyl, phenyl, phenethyl, t-butyl,
Figure imgf000132_0006
Figure imgf000132_0008
Figure imgf000132_0007
R10 phenyl, p-chlorophenyl, or p-trifluoromethylphenyl;
R1 1 is phenyl, benzyl, or 1-naphthyl; R12 is
Figure imgf000133_0008
. ,
Figure imgf000133_0009
, , ,
Figure imgf000133_0010
Figure imgf000133_0007
Figure imgf000133_0003
, ,
Figure imgf000133_0005
,
Figure imgf000133_0006
,
Figure imgf000133_0004
, or ; and
Figure imgf000133_0002
Figure imgf000133_0001
R13 is 1- or 2-naphthyl, phenyl, 4-chlorophenyl, 4- methylphenyl, 4-t-butylphenyl, n-butyl, or i-propyl;
or a pharmaceutically acceptable salt thereof.
9. A compound of Claim 4 of the formula:
Figure imgf000133_0011
wherein:
R1 is 6- or 7-OH when R2 is H;
R1 is 7-OH when R2 is CH3;
R4 and R5 is each methyl; or R4 and R5 taken together are -(CH2)5-,
-(CH2)2-O-(CH2)2-, -(CH2)2-NR8-(CH2)2-,
-CH2-NR8-(CH2)3-, -CH2-NR8-(CH2)2-, or -(CH2)2- CH(NHR8)(CH2)2-;
one of R6 and R7 is H and the other is OH or R6 and R7 taken together are =O or -S(CH2)2S-; and
R8 is
Figure imgf000134_0001
Figure imgf000135_0002
10. A compoimd of Claim 4 of the formula
Figure imgf000135_0001
wherein:
R1 is 6- or 7-OCH2C(O)NH(CH2) 1-6R17, or 6- or 7-OCH2-4- Phe-C(O)NH(CH2) 1-6R17 when R2 is H;
R1 1 is 7-OCH2C(O)NH(CH2) 1-6R17, or 7-OCH2-4-Phe- C(O)NH(CH2)1-6R17 when R2 is CH3; R4 and R5 is each methyl; or R4 and R5 taken together are -(CH2)5-, -(CH2)2-O-(CH2)2-, -(CH2)2-NR8-(CH2)2-,
-(CH2)2-CH(NHR8)(CH2)2-, -(CH2)2-S-(CH2)2- , or
-;
Figure imgf000136_0001
or R4 is methyl and R5 is CH2OCH3 or -(CH2)3N(Et)2; one of R6 and R7 is H and the other is OH; or R6 and R7 taken together are =O or -S(CH2)2S-; or one of R6 and R7 is H and the other is NAB, where A is methyl, 2-methoxyethyl, 2-phenylethyl, 4-methoxybenzyl, 2-tetrahydrofuranylmethyl, 2(3,4-dimethoxyphenyl)ethyl, or
2,2-diphenylethy! and B is
H, -SO2CH3 , , ,
Figure imgf000136_0002
Figure imgf000136_0003
, ,
Figure imgf000136_0005
Figure imgf000136_0004
, ,
Figure imgf000136_0006
Figure imgf000136_0007
Figure imgf000136_0008
Figure imgf000136_0010
, or
Figure imgf000136_0009
.
R8 is H, CONHCH3, SO2Ph, (CH2)3CH3, CO(CH2)2CH3, benzyl, -C(O)-(4-Phe)-SO2NH2, or
Figure imgf000136_0011
R13 is
H, -SO2CH3 , , ,
Figure imgf000137_0001
Figure imgf000137_0002
, ,
Figure imgf000137_0004
Figure imgf000137_0003
, ,
Figure imgf000137_0005
Figure imgf000137_0006
Figure imgf000137_0007
Figure imgf000137_0008
,or
Figure imgf000137_0009
;
(CH2)1-6R14 is methyl, n-butyl, 3-methoxy-n-propyl, CH2-c-propyl, or
-(CH2)1-3-phenyl; and
(CH2)1-6R17 is methyl, 2-methoxyethyl, 2-phenylethyl,
4-methoxybenzyl, methyl-2-tetrahydrofuranyl, 2(3,4-dimethoxyphenyl)ethyl, or 2,2-diphenylethyl;
or a pharmaceutically acceptable salt thereof.
11. A compound of Claim 4 of the formulae lIb, lIe, and lId:
Figure imgf000137_0010
Figure imgf000137_0012
Figure imgf000137_0011
wherein:
R1 is 6- or 7-OH, 6-or7-OCH2C(O)NH(CH2)1-6R17, or
6- or 7-OCH2-4-Phe-C(O)NH(CH2)1-6R17;
R2is HorCH3;
R8is -CO-Ph-p-SO2NH2; and
R6 and R7 together are =O or -SCH2CH2S-.
Figure imgf000138_0001
Figure imgf000138_0002
Figure imgf000139_0001
Figure imgf000140_0001
15. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 4 and a pharmaceutically acceptable carrier. 16. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 9 and a pharmaceutically acceptable carrier.
17. A pharmaceutical composition comprising a
therapeutically effective amount of a compound of Claim 10 and a pharmaceutically acceptable carrier.
18. A pharmaceutical composition for inhibiting carbonic anhydrase in a mammal comprising a therapeutically effective amount of a compound of Claim 1 1 and a pharmaceutically acceptable carrier.
19. A method of inhibiting carbonic anhydrase isozymes in a mammal which comprises administering to said mammal an effective amount of a compound of Claim 11. 20. A method of treating glaucoma in a mammal which comprises administering to a mammal in need of such treatment an effective amount of a compound of Claim 1 1.
21. A method of identifying a ligand having a desired characteristic which comprises synthesizing a combinatorial library of Claim 1 and testing the compounds in said library in an assay which identifies compounds having the desired characteristic.
22. A method of of Claim 21 wherein the compounds in said library are those wherein -C(O)-L'-II' is of the formula la.
23. A method of Claim 21 further comprising determining the structure of any ligand so identified.
24. A method of Claim 21 wherein said characteristic is carbonic anhydrase inhibition.
25. A method for identifying compounds that are inhibitors of carbonic anhydrase which comprises preparing a mixture of 20-300 pmol test compound and aqueous solutions (total volume: 25- 100 μL) of 0.03-1.2 μM carbonic anhydrase and 0.04-1.6 μM
dansylamide, exposing said mixture to U.V. (preferably 274 nm) light, and determining the amount of emitted U.V. (preferably 454 nm) light.
26. A method of Claim 25 wherein the total volume is about 50 μL, the carbonic anhydrase concentration is about 0.3 μM, the dansylamide concentration is about 0.6 μM, the mixture is exposed to 274 nm U.V. light, and the emitted U.V. light is 454 nm.
27. A method for identifying compounds that are enzyme inhibitors which is a lawn assay which comprises contacting a first layer which is a colloidal matrix containing enzyme, which matrix has embedded therein a mono-layer of solid supports with attached ligands, with a second layer which is contains a substrate which can be
monitored photometrically during its enzymic conversion to product, eluting said ligands by exposure to U.V. light, and detecting zones of inhibition in said first layer produced thereby.
28. A method of Claim 27 wherein said first layer is an agarose matrix containing bovine carbonic anhydrase and said second layer is a fluorescein diacetate-containing layer of agarose.
29. A method of identifying a ligand having a desired characteristic which comprises synthesizing a combinatorial library of Claim 1 , detaching the ligands from the solid supports in said library, and testing said library of ligands in an assay which identifies
compounds having the desired characteristic.
30. A method of Claim 29 further comprising determining the structure of any ligand so identified.
31. The use of divinylbenzene-cross-linked, polyethyleneglycol-grafted polystyrene beads as the solid supports for constructing combinatorial libraries of Claim 1.
32. A method of Claim 31 wherein the ligand is detached from said solid supports by photolysis.
33. A process for preparing a compound of the formula:
Figure imgf000142_0001
where R2 is H or lower alkyl; which comprises a) reacting allyl or methyl 4-(hydroxymethyl)-3-nitrobenzoate with a compound of the formula:
Figure imgf000143_0003
in the presence of triphenylphosphine, toluene, and DEAD and stirring the mixture at room temperature to produce
Figure imgf000143_0002
where R is allyl or methyl
and b) when R is allyl reacting said compound with methylene chloride, tetrakistriphenylphospine palladium(0), and pyrrolidine and stirring the mixture at 0°C, or when R is methyl reacting said compound with dilute NaOH and THF and stirring the mixture at 0°C.
34. A compound of the formula:
Figure imgf000143_0001
wherein:
ⓢ is a solid support;
R16 is lower alkyl, substituted lower alkyl, aryl, or substituted aryl;
R17 is H; alkyl substituted by 1-3 alkoxy, S-loweralkyl,
sulfamoyl, halo, alkylsulphonamido, or arylsulphonamido; alkenyl; alkynyl; aryl; substituted aryl; heteroaryl;
substituted heteroaryl; heterocycloalkyl; -CH2SC(O)R16;
-CH2NR16C(O)R16; -C(O)NR16R16; or -CH2OC(O)R16;
R is H or alkyl; and
Y is aryl or heteroaryl.
PCT/US1995/005940 1994-05-06 1995-05-08 Combinatorial dihydrobenzopyran library WO1995030642A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU25869/95A AU691296B2 (en) 1994-05-06 1995-05-08 Combinatorial dihydrobenzopyran library
EP95920411A EP0758313A4 (en) 1994-05-06 1995-05-08 Combinatorial dihydrobenzopyran library
JP7529207A JPH10500112A (en) 1994-05-06 1995-05-08 Combination dihydrobenzopyran library

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23930294A 1994-05-06 1994-05-06
US08/239,302 1994-05-06

Publications (1)

Publication Number Publication Date
WO1995030642A1 true WO1995030642A1 (en) 1995-11-16

Family

ID=22901570

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/005940 WO1995030642A1 (en) 1994-05-06 1995-05-08 Combinatorial dihydrobenzopyran library

Country Status (5)

Country Link
EP (1) EP0758313A4 (en)
JP (1) JPH10500112A (en)
AU (1) AU691296B2 (en)
CA (1) CA2189634A1 (en)
WO (1) WO1995030642A1 (en)

Cited By (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008835A1 (en) * 1996-08-26 1998-03-05 Pfizer Inc. Spirocyclic dopamine receptor subtype ligands
EP0905512A1 (en) * 1997-09-25 1999-03-31 Cerep Method of identification of leads or active compounds
US5908960A (en) * 1997-05-07 1999-06-01 Smithkline Beecham Corporation Compounds
US6004823A (en) * 1997-05-07 1999-12-21 Smithkline Beecham Corporation Compounds
WO2000032773A1 (en) 1998-11-27 2000-06-08 Darwin Discovery Ltd. Compositions and methods for increasing bone mineralization
US6242583B1 (en) 1996-05-24 2001-06-05 Basf Aktiengesellschaft Carbohydrate derivatives and their solid-phase synthesis
US6271345B1 (en) 1996-07-03 2001-08-07 Basf Aktiengesellschaft Enzyme cleavable linker bound to solid phase for organic compound synthesis
WO2001083751A2 (en) 2000-04-28 2001-11-08 Sangamo Biosciences, Inc. Methods for binding an exogenous molecule to cellular chromatin
JP2001526390A (en) * 1997-12-12 2001-12-18 アボット・ラボラトリーズ Continuous format high throughput screening
WO2002020509A2 (en) * 2000-09-06 2002-03-14 Bayer Aktiengesellschaft Medicaments against viral infections
US6362009B1 (en) 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
US6511808B2 (en) 2000-04-28 2003-01-28 Sangamo Biosciences, Inc. Methods for designing exogenous regulatory molecules
US6521780B1 (en) 1996-03-15 2003-02-18 Basf Aktiengesellschaft Cycloalkyl derivatives and the solid-phase synthesis of such derivatives
US6610489B2 (en) 2000-04-28 2003-08-26 Sangamo Biosciences, Inc. Pharmacogenomics and identification of drug targets by reconstruction of signal transduction pathways based on sequences of accessible regions
US6689558B2 (en) 2000-02-08 2004-02-10 Sangamo Biosciences, Inc. Cells for drug discovery
WO2004041067A2 (en) 2002-11-01 2004-05-21 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic disease
WO2004048552A2 (en) 2002-11-21 2004-06-10 Celltech R & D, Inc. Modulating immune responses
WO2004050895A2 (en) 2002-11-27 2004-06-17 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
WO2004069182A2 (en) 2003-02-01 2004-08-19 Neuralab Limited Active immunization to generate antibodies to soluble a-beta
US6790965B1 (en) 1994-05-06 2004-09-14 Pharmacopeia Drug Discovery, Inc. Combinatorial dihydrobenzopyran library
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
WO2005058940A2 (en) 2003-12-17 2005-06-30 Wyeth Immunogenic peptide carrier conjugates and methods of producing same
WO2006020581A2 (en) 2004-08-09 2006-02-23 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2006088950A2 (en) 2005-02-14 2006-08-24 University Of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
JP2007507532A (en) * 2003-10-01 2007-03-29 アドラー コーポレーション Spirocyclic heterocyclic derivatives and methods of using them
US7217509B2 (en) 2000-04-28 2007-05-15 Sangamo Biosciences, Inc. Databases of regulatory sequences; methods of making and using same
WO2007054580A1 (en) * 2005-11-14 2007-05-18 Solvay Pharmaceuticals Gmbh N-sulfamoyl-n’-benzopyranpiperidines as inhbitors of carbonic anhydrases
WO2007103374A2 (en) 2006-03-06 2007-09-13 Ceetox, Inc Toxicity screening methods
WO2008042024A2 (en) 2006-06-01 2008-04-10 Elan Pharmaceuticals, Inc. Neuroactive fragments of app
WO2008088688A1 (en) 2007-01-12 2008-07-24 Merck & Co., Inc. Substituted spirochromanone derivatives as acc inhibitors
WO2008088692A2 (en) 2007-01-12 2008-07-24 Merck & Co., Inc. Spirochromanon derivatives
US7410976B2 (en) 2005-07-19 2008-08-12 Merck & Co., Inc. Spirochromanone derivatives
EP1967525A2 (en) 2001-05-08 2008-09-10 Darwin Molecular Corporation A method for regulating immune function in primates using the foxp3 protein
EP1994937A2 (en) 1997-12-02 2008-11-26 Elan Pharma International Limited Prevention and treatment of amyloidogenic disease
EP2026073A1 (en) 2000-04-29 2009-02-18 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US7507546B2 (en) 2001-06-11 2009-03-24 Xenoport, Inc. Methods of screening agents, conjugates or conjugate moieties for transport by a PEPT2 transporter
US7547708B2 (en) 2005-11-14 2009-06-16 Solvay Pharmaceuticals, Inc. N-sulfamoyl-N′-benzopyranpiperidine compounds and uses thereof
WO2009078799A1 (en) 2007-12-17 2009-06-25 Marfl Ab New vaccine for the treatment of mycobacterium related disorders
WO2009086539A2 (en) 2007-12-28 2009-07-09 Elan Pharmaceuticals, Inc. Treatment and prophylaxis of amyloidosis
WO2009091586A2 (en) 2008-01-18 2009-07-23 North Carolina State University Peptides and methods of use as therapeutics and screening agents
US7572600B2 (en) 2004-08-04 2009-08-11 Chemocentryx, Inc. Enzymatic activities in chemokine-mediated inflammation
WO2010021415A1 (en) 2008-08-18 2010-02-25 Seoul National University Industry Foundation Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl trna synthetase
US7863029B2 (en) 2004-06-04 2011-01-04 Fox Chase Cancer Center Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
EP2272539A2 (en) 2004-10-19 2011-01-12 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in lewy body disease
US7887753B2 (en) 2000-11-16 2011-02-15 California Institute Of Technology Apparatus and methods for conducting assays and high throughput screening
EP2305302A2 (en) 1999-05-28 2011-04-06 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US7923542B2 (en) 2000-04-28 2011-04-12 Sangamo Biosciences, Inc. Libraries of regulatory sequences, methods of making and using same
EP2336147A2 (en) 2003-12-17 2011-06-22 Janssen Alzheimer Immunotherapy A beta immunogenic peptide carrier conjugates and methods of producing same
EP2338906A1 (en) 2003-06-16 2011-06-29 UCB Manufacturing, Inc. Compostion and methods for increasing bone mineralization
EP2361928A1 (en) 2003-05-19 2011-08-31 Elan Pharmaceuticals Inc. Truncated fragments of alpha-synuclein in Lewy body disease
EP2364719A1 (en) 1999-06-01 2011-09-14 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic diseases
US8153410B2 (en) 2003-07-07 2012-04-10 Fox Chase Cancer Center Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
EP2450056A1 (en) 2005-07-19 2012-05-09 Elan Pharma International Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
US8193328B2 (en) 2005-09-08 2012-06-05 Philadelphia Health & Education Corporation Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents
WO2013055101A1 (en) 2011-10-10 2013-04-18 Medicinal Bioconvergence Research Center Method for screening an agent preventing or treating cancer using glycyl-trna synthetase and cadherin
EP2583978A2 (en) 2007-02-23 2013-04-24 The Regents of the University of California Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2013078138A1 (en) 2011-11-21 2013-05-30 OSI Pharmaceuticals, LLC Proton nmr spectroscopy for biochemical screening
US8524730B2 (en) 2008-07-04 2013-09-03 Msd K.K. Spirochromanone carboxylic acids
US8598164B2 (en) 2010-05-06 2013-12-03 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
US8828996B2 (en) 2011-03-14 2014-09-09 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
US8889703B2 (en) 2010-02-24 2014-11-18 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
US8916565B2 (en) 2011-02-02 2014-12-23 Vertex Pharmaceuticals Incorporated Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
US8962912B2 (en) 2007-12-31 2015-02-24 Baxter International Inc. Transgenic non-human animals expressing human blood clotting factors and uses thereof
US8969255B2 (en) 2009-06-19 2015-03-03 The Arizona Board Of Regents Compound arrays for sample profiling
US8975293B2 (en) 2011-05-26 2015-03-10 Regents Of The University Of Michigan Epigenetic co-repressors of the gamma-globin gene and methods of using same
US8981112B2 (en) 2012-03-05 2015-03-17 Vitae Pharmaceuticals, Inc. Inhibitors of β-secretase
US9018391B2 (en) 2012-08-27 2015-04-28 Boehringer Ingelheim International Gmbh Inhibitors of beta-secretase
US9212153B2 (en) 2009-03-13 2015-12-15 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
WO2016040895A1 (en) 2014-09-12 2016-03-17 xxTHE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Wnt signaling agonist molecules
US9290477B2 (en) 2012-09-28 2016-03-22 Vitae Pharmaceuticals, Inc. Inhibitors of β-secretase
WO2016100857A1 (en) 2014-12-19 2016-06-23 Regeneron Pharmaceuticals, Inc. Stem cells for modeling type 2 diabetes
US9435807B2 (en) 2011-09-22 2016-09-06 Medicinal Bioconvergence Research Center Use of leucyl tRNA synthetase
EP3067066A1 (en) 2007-02-23 2016-09-14 Prothena Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US9678062B2 (en) 2011-09-23 2017-06-13 University Of Louisville Research Foundation, Inc. Methods and compositions for expanding cells and improving engraftment
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2018007979A1 (en) 2016-07-06 2018-01-11 Prothena Biosciences Limited Assay for detecting total and s129 phosphorylated alpha-synuclein
WO2018023014A1 (en) 2016-07-29 2018-02-01 Regeneron Pharmaceuticals, Inc. Mice comprising mutations resulting in expression of c-truncated fibrillin-1
WO2018071493A1 (en) 2016-10-12 2018-04-19 Janssen Biotech, Inc. Methods for screening for modulators of gdf15-like biological activity
US9970932B2 (en) 2013-03-15 2018-05-15 Arizona Board Of Regents On Behalf Of Arizona State University Non-covalent patterned chemical features and use thereof in MALDI-based quality control
US10006919B2 (en) 2013-03-15 2018-06-26 Arizona Board Of Regents On Behalf Of Arizona State University Peptide array quality control
WO2018202850A1 (en) 2017-05-05 2018-11-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Microtubule-targeting drugs as immune checkpoint inhibitors and methods of screening novel immune checkpoint inhibitors for the treatment of cancers and infectious diseases
WO2019094735A1 (en) 2017-11-10 2019-05-16 Regeneron Pharmaceuticals, Inc. Non-human animals comprising slc30a8 mutation and methods of use
US10385070B2 (en) 2011-02-18 2019-08-20 Vertex Pharmaceuticals Incorporated Chroman-spirocyclic piperidine amides as modulators of ion channels
WO2020016433A1 (en) 2018-07-20 2020-01-23 Aicuris Gmbh & Co. Kg Methods for screening and identifying agents that inhibit or modulate the nuclear egress complex of herpesviruses
US10758886B2 (en) 2015-09-14 2020-09-01 Arizona Board Of Regents On Behalf Of Arizona State University Conditioned surfaces for in situ molecular array synthesis
WO2020210724A1 (en) 2019-04-10 2020-10-15 University Of Utah Research Foundation Htra1 modulation for treatment of amd
US11371990B2 (en) 2016-11-11 2022-06-28 Cowper Sciences Inc. Methods for identifying candidate biomarkers
WO2022235929A1 (en) 2021-05-05 2022-11-10 Radius Pharmaceuticals, Inc. Animal model having homologous recombination of mouse pth1 receptor
US11747334B2 (en) 2016-06-20 2023-09-05 Cowper Sciences Inc. Methods for differential diagnosis of autoimmune diseases
US11774446B2 (en) 2016-06-20 2023-10-03 Cowper Sciences Inc. Methods for diagnosis and treatment of autoimmune diseases
US11971410B2 (en) 2022-02-15 2024-04-30 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092179A1 (en) * 2003-04-14 2004-10-28 Nippon Soda Co. Ltd. Spiro derivative, production process, and antioxidant

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499299A (en) * 1981-12-30 1985-02-12 Ici Americas Inc. Pharmaceutically active phenylcarboxylic acid derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0230475B1 (en) * 1985-08-05 1992-03-18 Mitsui Petrochemical Industries, Ltd. Novel urea derivatives, processes for production thereof and herbicide
WO1994008051A1 (en) * 1992-10-01 1994-04-14 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499299A (en) * 1981-12-30 1985-02-12 Ici Americas Inc. Pharmaceutically active phenylcarboxylic acid derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ABSTRACT, MITSUI PETROCHEMICAL INDUSTRIES, Abstract 236509B; & WO,A,87 00840, February 1987. *
J. MED. CHEM., Volume 32, Number 4, issued April 1989, BROWN et al., "Hydroxyacetophenone-Derived Antagonists of the Peptidoleukotrienes", pages 807-826. *
See also references of EP0758313A4 *

Cited By (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790965B1 (en) 1994-05-06 2004-09-14 Pharmacopeia Drug Discovery, Inc. Combinatorial dihydrobenzopyran library
US6521780B1 (en) 1996-03-15 2003-02-18 Basf Aktiengesellschaft Cycloalkyl derivatives and the solid-phase synthesis of such derivatives
US6242583B1 (en) 1996-05-24 2001-06-05 Basf Aktiengesellschaft Carbohydrate derivatives and their solid-phase synthesis
US6271345B1 (en) 1996-07-03 2001-08-07 Basf Aktiengesellschaft Enzyme cleavable linker bound to solid phase for organic compound synthesis
WO1998008835A1 (en) * 1996-08-26 1998-03-05 Pfizer Inc. Spirocyclic dopamine receptor subtype ligands
US6664258B1 (en) 1996-08-26 2003-12-16 Pfizer Inc Spirocyclic dopamine receptor subtype ligands
US6004823A (en) * 1997-05-07 1999-12-21 Smithkline Beecham Corporation Compounds
US5908960A (en) * 1997-05-07 1999-06-01 Smithkline Beecham Corporation Compounds
WO1999015894A3 (en) * 1997-09-25 1999-08-19 Cerep Method of identification of leads or active compounds
EP0905512A1 (en) * 1997-09-25 1999-03-31 Cerep Method of identification of leads or active compounds
WO1999015894A2 (en) * 1997-09-25 1999-04-01 Cerep Method of identification of leads or active compounds
US6362009B1 (en) 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
EP2305282A2 (en) 1997-12-02 2011-04-06 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
EP1994937A2 (en) 1997-12-02 2008-11-26 Elan Pharma International Limited Prevention and treatment of amyloidogenic disease
JP2001526390A (en) * 1997-12-12 2001-12-18 アボット・ラボラトリーズ Continuous format high throughput screening
EP2261335A1 (en) 1998-11-27 2010-12-15 UCB Pharma S.A. Compositions and methods for increasing bone mineralisation
WO2000032773A1 (en) 1998-11-27 2000-06-08 Darwin Discovery Ltd. Compositions and methods for increasing bone mineralization
EP1721979A1 (en) 1998-11-27 2006-11-15 Ucb, S.A. Compositions and methods for increasing bone mineralisation
EP2305302A2 (en) 1999-05-28 2011-04-06 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
EP2364719A1 (en) 1999-06-01 2011-09-14 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic diseases
US7479495B2 (en) 1999-12-28 2009-01-20 Pharmacopeia, Inc. N-heterocyclic inhibitors of TNF-α expression
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
US7045304B2 (en) 2000-02-08 2006-05-16 Sangamo Biosciences, Inc. Cells for drug discovery
US6989269B2 (en) 2000-02-08 2006-01-24 Sangamo Biosciences, Inc. Cells for drug discovery
US6689558B2 (en) 2000-02-08 2004-02-10 Sangamo Biosciences, Inc. Cells for drug discovery
EP2207032A1 (en) 2000-02-08 2010-07-14 Sangamo BioSciences, Inc. Cells expressing zinc finger protein for drug discovery
US7217509B2 (en) 2000-04-28 2007-05-15 Sangamo Biosciences, Inc. Databases of regulatory sequences; methods of making and using same
US6610489B2 (en) 2000-04-28 2003-08-26 Sangamo Biosciences, Inc. Pharmacogenomics and identification of drug targets by reconstruction of signal transduction pathways based on sequences of accessible regions
WO2001083751A2 (en) 2000-04-28 2001-11-08 Sangamo Biosciences, Inc. Methods for binding an exogenous molecule to cellular chromatin
US7097978B2 (en) 2000-04-28 2006-08-29 Sangamo Biosciences, Inc. Screening methods based on isolating a collection of polynucleotides corresponding to accessible regions of chromatin
US6511808B2 (en) 2000-04-28 2003-01-28 Sangamo Biosciences, Inc. Methods for designing exogenous regulatory molecules
US7923542B2 (en) 2000-04-28 2011-04-12 Sangamo Biosciences, Inc. Libraries of regulatory sequences, methods of making and using same
EP2026073A1 (en) 2000-04-29 2009-02-18 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
WO2002020509A2 (en) * 2000-09-06 2002-03-14 Bayer Aktiengesellschaft Medicaments against viral infections
WO2002020509A3 (en) * 2000-09-06 2002-06-27 Bayer Ag Medicaments against viral infections
US8455258B2 (en) 2000-11-16 2013-06-04 California Insitute Of Technology Apparatus and methods for conducting assays and high throughput screening
US10509018B2 (en) 2000-11-16 2019-12-17 California Institute Of Technology Apparatus and methods for conducting assays and high throughput screening
US8273574B2 (en) 2000-11-16 2012-09-25 California Institute Of Technology Apparatus and methods for conducting assays and high throughput screening
US9176137B2 (en) 2000-11-16 2015-11-03 California Institute Of Technology Apparatus and methods for conducting assays and high throughput screening
EP2381116A1 (en) 2000-11-16 2011-10-26 California Institute of Technology Apparatus and methods for conducting assays and high throughput screening
US7887753B2 (en) 2000-11-16 2011-02-15 California Institute Of Technology Apparatus and methods for conducting assays and high throughput screening
US8673645B2 (en) 2000-11-16 2014-03-18 California Institute Of Technology Apparatus and methods for conducting assays and high throughput screening
EP1967525A2 (en) 2001-05-08 2008-09-10 Darwin Molecular Corporation A method for regulating immune function in primates using the foxp3 protein
US7919454B2 (en) 2001-06-11 2011-04-05 Xenoport, Inc. Methods of treating using conjugates transported by a PEPT2 transporter
US7507546B2 (en) 2001-06-11 2009-03-24 Xenoport, Inc. Methods of screening agents, conjugates or conjugate moieties for transport by a PEPT2 transporter
WO2004041067A2 (en) 2002-11-01 2004-05-21 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic disease
EP2361629A1 (en) 2002-11-01 2011-08-31 Elan Pharmaceuticals Inc. Prevention and treatment of synucleinopathic disease
EP2258724A1 (en) 2002-11-21 2010-12-08 Celltech R & D, Inc. Modulating immune responses using multimerized anti-CD83 antibodies
WO2004048552A2 (en) 2002-11-21 2004-06-10 Celltech R & D, Inc. Modulating immune responses
WO2004050895A2 (en) 2002-11-27 2004-06-17 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
WO2004069182A2 (en) 2003-02-01 2004-08-19 Neuralab Limited Active immunization to generate antibodies to soluble a-beta
EP2361928A1 (en) 2003-05-19 2011-08-31 Elan Pharmaceuticals Inc. Truncated fragments of alpha-synuclein in Lewy body disease
EP2338906A1 (en) 2003-06-16 2011-06-29 UCB Manufacturing, Inc. Compostion and methods for increasing bone mineralization
EP2341071A1 (en) 2003-06-16 2011-07-06 UCB Manufacturing, Inc. Compostion and methods for increasing bone mineralization
US8153410B2 (en) 2003-07-07 2012-04-10 Fox Chase Cancer Center Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
JP2007507532A (en) * 2003-10-01 2007-03-29 アドラー コーポレーション Spirocyclic heterocyclic derivatives and methods of using them
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
EP2460813A1 (en) 2003-12-17 2012-06-06 Janssen Alzheimer Immunotherapy A beta immunogenic peptide carrier conjugates and methods of producing same
EP2479184A2 (en) 2003-12-17 2012-07-25 Janssen Alzheimer Immunotherapy Beta immunogenic peptide carrier conjugates and methods of producing the same
EP2336147A2 (en) 2003-12-17 2011-06-22 Janssen Alzheimer Immunotherapy A beta immunogenic peptide carrier conjugates and methods of producing same
WO2005058940A2 (en) 2003-12-17 2005-06-30 Wyeth Immunogenic peptide carrier conjugates and methods of producing same
US7863029B2 (en) 2004-06-04 2011-01-04 Fox Chase Cancer Center Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
US7572600B2 (en) 2004-08-04 2009-08-11 Chemocentryx, Inc. Enzymatic activities in chemokine-mediated inflammation
EP3369433A1 (en) 2004-08-09 2018-09-05 Janssen Alzheimer Immunotherapy Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2006020581A2 (en) 2004-08-09 2006-02-23 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
EP2272539A2 (en) 2004-10-19 2011-01-12 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in lewy body disease
EP2371396A1 (en) 2004-10-19 2011-10-05 Elan Pharmaceuticals Inc. Truncated fragments of alpha synuclein in lewy body disease
EP2302076A1 (en) 2005-02-14 2011-03-30 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
EP2357254A1 (en) 2005-02-14 2011-08-17 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
WO2006088950A2 (en) 2005-02-14 2006-08-24 University Of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
US7410976B2 (en) 2005-07-19 2008-08-12 Merck & Co., Inc. Spirochromanone derivatives
EP2450056A1 (en) 2005-07-19 2012-05-09 Elan Pharma International Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US7935712B2 (en) 2005-07-19 2011-05-03 Merck Sharp & Dohme Corp. Spirochromanone derivatives as acetyl coenzyme A carboxylase (ACC) inhibitors
US8193328B2 (en) 2005-09-08 2012-06-05 Philadelphia Health & Education Corporation Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents
US7547708B2 (en) 2005-11-14 2009-06-16 Solvay Pharmaceuticals, Inc. N-sulfamoyl-N′-benzopyranpiperidine compounds and uses thereof
WO2007054580A1 (en) * 2005-11-14 2007-05-18 Solvay Pharmaceuticals Gmbh N-sulfamoyl-n’-benzopyranpiperidines as inhbitors of carbonic anhydrases
WO2007103374A2 (en) 2006-03-06 2007-09-13 Ceetox, Inc Toxicity screening methods
EP2287327A1 (en) 2006-03-06 2011-02-23 Ceetox Inc. In vitro anti tumor compound toxicity screening methods
WO2008042024A2 (en) 2006-06-01 2008-04-10 Elan Pharmaceuticals, Inc. Neuroactive fragments of app
US8093389B2 (en) 2007-01-12 2012-01-10 Merck Sharp & Dohme Corp. Substituted spirochromanone derivatives
US8138197B2 (en) 2007-01-12 2012-03-20 Msd K.K. Spirochromanon derivatives
WO2008088692A2 (en) 2007-01-12 2008-07-24 Merck & Co., Inc. Spirochromanon derivatives
WO2008088688A1 (en) 2007-01-12 2008-07-24 Merck & Co., Inc. Substituted spirochromanone derivatives as acc inhibitors
EP3067066A1 (en) 2007-02-23 2016-09-14 Prothena Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
EP2583978A2 (en) 2007-02-23 2013-04-24 The Regents of the University of California Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2009078799A1 (en) 2007-12-17 2009-06-25 Marfl Ab New vaccine for the treatment of mycobacterium related disorders
US8779088B2 (en) 2007-12-17 2014-07-15 Marfl Ab Vaccine for the treatment of Mycobacterium related disorders
US8636981B2 (en) 2007-12-28 2014-01-28 Onclave Therapeutics Detection of amyloid deposits using anti-amyloid antibodies
EP3693470A1 (en) 2007-12-28 2020-08-12 Prothena Therapeutics Limited Treatment and prophylaxis of amyloidosis
US7928203B2 (en) 2007-12-28 2011-04-19 Elan Pharmaceuticals, Inc. Chimeric, humanized, or human antibody 2A4
US8268973B2 (en) 2007-12-28 2012-09-18 Onclave Therapeutics Anti-amyloid antibodies
WO2009086539A2 (en) 2007-12-28 2009-07-09 Elan Pharmaceuticals, Inc. Treatment and prophylaxis of amyloidosis
EP2730659A2 (en) 2007-12-28 2014-05-14 Elan Pharmaceuticals Inc. Treatment and Prophylaxis of Amyloidosis
US8404815B2 (en) 2007-12-28 2013-03-26 Onclave Therapeutics Chimeric, humanized, or human antibody 2A4
US8791243B2 (en) 2007-12-28 2014-07-29 Onclave Therapeutics Limited Treatment and prophylaxis of amyloidosis
US8962912B2 (en) 2007-12-31 2015-02-24 Baxter International Inc. Transgenic non-human animals expressing human blood clotting factors and uses thereof
WO2009091586A2 (en) 2008-01-18 2009-07-23 North Carolina State University Peptides and methods of use as therapeutics and screening agents
US8524730B2 (en) 2008-07-04 2013-09-03 Msd K.K. Spirochromanone carboxylic acids
WO2010021415A1 (en) 2008-08-18 2010-02-25 Seoul National University Industry Foundation Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl trna synthetase
US10336717B2 (en) 2009-03-13 2019-07-02 Vitae Pharmaceuticals, Llc Inhibitors of beta-secretase
US9212153B2 (en) 2009-03-13 2015-12-15 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
US10422793B2 (en) 2009-06-19 2019-09-24 Arizona Board Of Regents On Behalf Of Arizona State University Compound arrays for sample profiling
US9709558B2 (en) 2009-06-19 2017-07-18 Arizona Board Of Regents On Behalf Of Arizona State University Compound arrays for sample profiling
US8969255B2 (en) 2009-06-19 2015-03-03 The Arizona Board Of Regents Compound arrays for sample profiling
US8889703B2 (en) 2010-02-24 2014-11-18 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
US8598164B2 (en) 2010-05-06 2013-12-03 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
US9511067B2 (en) 2011-02-02 2016-12-06 Vertex Pharmaceuticals Incorporated Substituted spiro[piperidine-4,1'-pyrrolo[1,2-a]pyrazine]s as modulators of ion channels
US8916565B2 (en) 2011-02-02 2014-12-23 Vertex Pharmaceuticals Incorporated Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
US10385070B2 (en) 2011-02-18 2019-08-20 Vertex Pharmaceuticals Incorporated Chroman-spirocyclic piperidine amides as modulators of ion channels
US9181273B2 (en) 2011-03-14 2015-11-10 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
US8828996B2 (en) 2011-03-14 2014-09-09 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
US8975293B2 (en) 2011-05-26 2015-03-10 Regents Of The University Of Michigan Epigenetic co-repressors of the gamma-globin gene and methods of using same
US9435807B2 (en) 2011-09-22 2016-09-06 Medicinal Bioconvergence Research Center Use of leucyl tRNA synthetase
US9678062B2 (en) 2011-09-23 2017-06-13 University Of Louisville Research Foundation, Inc. Methods and compositions for expanding cells and improving engraftment
WO2013055101A1 (en) 2011-10-10 2013-04-18 Medicinal Bioconvergence Research Center Method for screening an agent preventing or treating cancer using glycyl-trna synthetase and cadherin
US9274113B2 (en) 2011-10-10 2016-03-01 Medicinal Bioconvergence Research Center Method for screening an agent preventing or treating cancer using glycyl-tRNA synthetase and cadherin
WO2013078138A1 (en) 2011-11-21 2013-05-30 OSI Pharmaceuticals, LLC Proton nmr spectroscopy for biochemical screening
US9526727B2 (en) 2012-03-05 2016-12-27 Vitae Pharmaceutical, Inc. Inhibitors of beta-secretase
US8981112B2 (en) 2012-03-05 2015-03-17 Vitae Pharmaceuticals, Inc. Inhibitors of β-secretase
US9949975B2 (en) 2012-03-05 2018-04-24 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
US9018391B2 (en) 2012-08-27 2015-04-28 Boehringer Ingelheim International Gmbh Inhibitors of beta-secretase
US9290477B2 (en) 2012-09-28 2016-03-22 Vitae Pharmaceuticals, Inc. Inhibitors of β-secretase
US11067582B2 (en) 2013-03-15 2021-07-20 Arizona Board Of Regents On Behalf Of Arizona State University Peptide array quality control
US10006919B2 (en) 2013-03-15 2018-06-26 Arizona Board Of Regents On Behalf Of Arizona State University Peptide array quality control
US9970932B2 (en) 2013-03-15 2018-05-15 Arizona Board Of Regents On Behalf Of Arizona State University Non-covalent patterned chemical features and use thereof in MALDI-based quality control
US10578623B2 (en) 2013-03-15 2020-03-03 Arizona Board of Regents of behalf of Arizona State University Peptide array quality control
WO2016040895A1 (en) 2014-09-12 2016-03-17 xxTHE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Wnt signaling agonist molecules
EP4219564A1 (en) 2014-09-12 2023-08-02 The Board of Trustees of the Leland Stanford Junior University Wnt signaling agonist molecules
WO2016100857A1 (en) 2014-12-19 2016-06-23 Regeneron Pharmaceuticals, Inc. Stem cells for modeling type 2 diabetes
US10758886B2 (en) 2015-09-14 2020-09-01 Arizona Board Of Regents On Behalf Of Arizona State University Conditioned surfaces for in situ molecular array synthesis
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
US11774446B2 (en) 2016-06-20 2023-10-03 Cowper Sciences Inc. Methods for diagnosis and treatment of autoimmune diseases
US11747334B2 (en) 2016-06-20 2023-09-05 Cowper Sciences Inc. Methods for differential diagnosis of autoimmune diseases
WO2018007979A1 (en) 2016-07-06 2018-01-11 Prothena Biosciences Limited Assay for detecting total and s129 phosphorylated alpha-synuclein
WO2018023014A1 (en) 2016-07-29 2018-02-01 Regeneron Pharmaceuticals, Inc. Mice comprising mutations resulting in expression of c-truncated fibrillin-1
WO2018071493A1 (en) 2016-10-12 2018-04-19 Janssen Biotech, Inc. Methods for screening for modulators of gdf15-like biological activity
US11371990B2 (en) 2016-11-11 2022-06-28 Cowper Sciences Inc. Methods for identifying candidate biomarkers
WO2018202850A1 (en) 2017-05-05 2018-11-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Microtubule-targeting drugs as immune checkpoint inhibitors and methods of screening novel immune checkpoint inhibitors for the treatment of cancers and infectious diseases
WO2019094735A1 (en) 2017-11-10 2019-05-16 Regeneron Pharmaceuticals, Inc. Non-human animals comprising slc30a8 mutation and methods of use
WO2020016433A1 (en) 2018-07-20 2020-01-23 Aicuris Gmbh & Co. Kg Methods for screening and identifying agents that inhibit or modulate the nuclear egress complex of herpesviruses
WO2020210724A1 (en) 2019-04-10 2020-10-15 University Of Utah Research Foundation Htra1 modulation for treatment of amd
WO2022235929A1 (en) 2021-05-05 2022-11-10 Radius Pharmaceuticals, Inc. Animal model having homologous recombination of mouse pth1 receptor
US11971410B2 (en) 2022-02-15 2024-04-30 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer

Also Published As

Publication number Publication date
EP0758313A4 (en) 1999-09-15
EP0758313A1 (en) 1997-02-19
AU2586995A (en) 1995-11-29
AU691296B2 (en) 1998-05-14
JPH10500112A (en) 1998-01-06
CA2189634A1 (en) 1995-11-16

Similar Documents

Publication Publication Date Title
US5821130A (en) Combinatorial dihydrobenzopyran library
US6017768A (en) Combinatorial dihydrobenzopyran library
WO1995030642A1 (en) Combinatorial dihydrobenzopyran library
WO1997016729A9 (en) Combinatorial dihydrobenzopyran library
AU690656B2 (en) Sulfonamide derivatives and their use
US5766963A (en) Combination hydroxypropylamine library
US5962337A (en) Combinatorial 1,4-benzodiazepin-2,5-dione library
Blankley et al. Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtype
US6255120B1 (en) Combinatorial library of substituted statine esters and amides via a novel acid-catalyzed rearrangement
JPH08506175A (en) Combinatorial chemical library of tag-encoded complexes
EP1362052B1 (en) Inhibitors of cruzipain and other cysteine proteases
JP2006504651A (en) Bioactive compounds
US5798352A (en) Antithrombotic amidinotetrahydropyridylalanine derivatives
US6150344A (en) Hydroxyphosphonate peptidomimetics as inhibitors of aspartyl proteases
KR100704009B1 (en) 6-Alkylamino-2-methyl-2'-N-methyl substituted sulfonamidomethyl-2H-1-benzopyran derivatives as anti-inflammatory inhibitors
US5986102A (en) Hydroxypropylamide peptidomimetics as inhibitors of aspartyl proteases
KR101087883B1 (en) Amines that inhibit a mammalian anandamide transporter, and methods of use thereof
US6790965B1 (en) Combinatorial dihydrobenzopyran library
AU7675096A (en) Combinatorial dihydrobenzopyran library
St Laurent et al. Active site-directed thrombin inhibitors-II. Studies related to arginine/guanidine bioisosteres
TAKAI et al. Synthesis of 1-and 3-(1-Substituted 4-Piperidinyl)-1, 2, 3, 4-tetrahydro-2-oxoquinazolines as Potential Antihypertensive Agents
JP4336299B2 (en) 6-alkylamino-2,2'-double-substituted-7,8-double-substituted-2H-1-benzopyran derivatives having 5-lipoxygenase inhibitory activity
EP1042322B1 (en) Kv2.1 ANTAGONISTS
CA2304783A1 (en) Method of identification of leads or active compounds
CN114230630B (en) Triptolide derivative and application thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2189634

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995920411

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995920411

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1995920411

Country of ref document: EP